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ABSTRACT OF THE DISSERTATION
Resveratrol Regulates IGF-II and Cathepsin D in Breast Cancer Cells
by
Sharda Kalla Vyas
Doctor of Philosophy, Graduate Program in Anatomy
Loma Linda University, Loma Linda California, June 2005
Daisy D. De Leon, Chairperson
Breast cancer is the most common type of cancer among women in the US.
Phytoestrogen resveratrol (RS V) has been described as a potential ehemotherapeutic
agent, but has been associated with breast cancer cell growth and cell death. RSV binds
to estrogen receptors (ER) and functions as a mixed estrogen agonist/antagonist. The
mechanism by which RSV regulates breast cancer growth is largely unknown, but it
likely targets factors regulated by estrogens. Insulin-like growth factor II (IGF-II) and its
precursor (proIGF-II) are estrogen-regulated mitogens that are over-expressed in breast
carcinoma. Thus, I hypothesized that IGF-II/proIGF-II might mediate the biphasic
effects of RSV on breast cancer cell growth.
The hypothesis was tested by the following specific aims: (I) Determine RSV
modulation of breast cancer cell growth in ER +/- cells; (2) Identify the effect of RSV on
IGF-II/proIGF-II expression in breast cancer cells; (3) Determine whether IGF-
II/proIGF-II mediates RSV effects on breast cancer cells; (4) Identify IGF-II/proIGF-II
targets involved in breast cancer cell modulation - i.e. apoptotie genes and Cathepsin D
(CD), an estrogen-regulated protein elevated in breast cancer.
RSV displays a biphasic effect on cell growth and IGF-II expression in ER+ breast
carcinoma cells. In ER+ cells (MCF-7, T47D), RSV at lO'^M induces a 2-fold increase
Xll
in cell growth with an increase in proIGF-II expression (2.5 fold by Northern) and
seeretion (2 fold by Western) 24 hr post-treatment. While RSV at lO'^^M inhibited cell
growth, deereased proIGF-II expression, and redueed proIGF-II secretion (by 50%, 50%
and 30%, respectively). Furthermore, bloeking antibody to the IGF-I receptor (mediator
of IGF-II signal transduetion) completely inhibited the growth stimulatory effeet of RSV
10'^ M. In contrast, ER- cells (MCF-lOA, Hs578t) showed no RSV-related inerease in
growth or changes in IGF-II/proIGF-II expression.
Over-expression of IGF-II, either endogenous or exogenous via an expression
plasmid, induced an increase in CD secretion (2 fold) irrespective of ER status. In
addition, the RSV (10"^M)-induced down-regulation of IGF-II led to a decrease in the
anti-apoptotic proteins Bcl-2 and survivin (2.5 and 2 fold respeetively) that could be
reversed by exogenous proIGF-II (lOOng/ml) or by over-expression of a proIGF-II
expression plasmid.
In summary, these data demonstrate that RSV could increase the risk of breast cancer
growth at low coneentration by increasing proIGF-II levels. Furthermore, these data
suggest that IGF-II/proIGF-II manifests its effeets on breast cancer growth by inducing




Breast cancer results after normal mammary epithelial cells sustain genetic
damage to acquire the phenolypes characteristic of malignancy: unregulated
proliferation, protection from cell death, and ability to metastasize. In addition to
estrogen, breast cancer cells respond to various stimuli including growth factors.
Since breast cancer metastasis is directly associated with death rate, identifying and
understanding the growth regulatory pathways involved in breast cancer progression
is essential to identify new therapeutic targets.
Recently, resveratrol (RSV, 3,5,4'-trihydroxy-tra«5-stilbene) has been described
as a potential chemotherapeutic agent for breast cancer. RSV is a naturally occurring
phytochemical that can be found in approximately 72 plant species, and is presently
considered a potential chemopreventive treatment for breast cancer. RSV can act as both
a mixed agonist/antagonist for ERs a and P, although the mechanism of action for this
phytoestrogen and its target genes are mostly unknown. Whereas some investigators have
demonstrated antiproliferative effects in the MDA-MB-231, KPC-I, MKL-F, T47D and
MCF-7 cell lines (Clemment et al. 1998, Mgbonyebi et al 1998, Nakagawa et al. 2001),
others have demonstrated growth enhancement in T47D and MCF-7 cells (Gehm et al.
1997, Basly et al. 2000). The latter effect appears to be due to the potential estrogenic
effects of RSV. However, the precise mechanisms by which RSV exerts these biphasic
effects are not well known, but likely involve the modulation of specific estrogen-
regulated targets.
The insulin-like growth factor-II (IGF-II) is a potent estrogen-regulated mitogen
that stimulates cell proliferation and inhibits apoptosis of breast cancer cells. IGF-II gene
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expression is paternally imprinted and regulated by tumor suppressor genes such as p53,
WTl (Wilms' tumor gene), GC factor (GCF) (Zhang et al. 1996, Toretsky and Helman
196, Kitadai et al. 1993) and as mentioned by 17-Estradiol (E2) (Yee and Lee, 2000).
Furthermore, the complex regulation of IGF-II expression involves both,
developmentally regulated promoters (P1-P4) and alternative splicing of different
untranslated leader sequences (Werner et al. 1994). IGF-II is translated as a prohormone
that is cleaved and glycosylated to produce isoforms ranging from 21 (proIGF-II) to 7.5
kDa (mature IGF-II) (Gowan et al. 1987). ProIGF-II is the predominant form secreted by
most tumors and it is biologically active (Gowan et al. 1987, Hoppener et al. 1988, Reeve
et al. 1995, Hasselbacher et al. 1987). While IGF-II overexpression does not cause
malignant tumor growth in some organs, such as the uterus (Ward et al. 1994), in the
mammary gland excess IGF-II contributes to tumor formation. This provides evidence for
the role of IGF-II signaling in malignant transformation. IGF-II also plays a role in the
maintenance of the malignant phenotype. It has also been shown that malignant breast
epithelial cells can induce expression of IGF-II in the stroma in vitro. IGF-II binds
several receptors including the IGF-II/Mannose 6-phosphate receptor (IGF-II/M6PR),
IGF-I receptor (IGF-IR) and the insulin receptor isoform A (IR-A). IGF-II mitogenic
effects are mediated through the IGF-IR and the IR-A while insulin binding to IR-A
stimulates metabolic pathways (Sciacca et al 1999, Sciacca et al. 2002, Denley et al.
2004). IGF-II binding to the IGF-II/M-6-P receptor results in intracellular degradation of
IGF-II and decreased signaling through the IGF-I and IR-A receptors (Scott and Firth
2004). The IGF-II/M6PR binds both IGF-II and other mannose 6 phosphate substrates
such as Cathepsin D, which have separate binding sites. Our laboratory has previously
shown that expression of pro-IGF-II leads to an increase in Cathepsin D secretion in
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MCF-7 breast cancer cells (DeLeon et al. 1996).
Cathepsin D (CD) is an aspartyl protease regulated by estrogen and overexpressed
in a variety of human cancers including estrogen receptor (ER) negative breast
carcinomas (Rochefort et al, 1989). Cathepsin D is synthesized as preprocathepsin D
(pCD). The single chain procathepsin D (52 kDa) is autoactivated to CD (51 kDa) and
further processed and glycosylated into several distinct forms (51-14 kDa), which are
enzymatically active forms (Westley et al. 1996, Iwase et al. 1997). In estrogen receptor
(ER) positive breast cancer cells, overexpression of procathepsin D has been correlated
with lymphatic metastasis, relapse and short disease survival in several retrospective
clinical studies (Brouillet et al. 1997, Rochefort et al. 1996). The CD gene has a mixed
structure with the general features of housekeeping genes (constitutively secreted, high
G+C content and potential Spl binding sites) and those of a regulated facultative gene
that includes a TATAA sequence. In ER positive breast cancer eell lines, CD is regulated
by npestradiol (E2). Transcription from the CD gene can be initiated at five sites
spanning 52 bp; of the five start sites, estrogen stimulates transcription only from the site
located downstream of the TATA box at -20; in contrast, low proportions of TATA-
dependent transcription were observed in estrogen-unresponsive breast cancer cell lines,
suggesting that factors other than estrogens may also stimulate TATA-dependent
transcription. In TATA-independent transcription, like observed in ER(-) cell lines, the
proportion of longer CD mRNA is increased. This effect might have biological
consequences in terms of stability or initiation of translation and subcellular localization
of the protein (Cavailles et al, 1993). ER targeting of upstream stimulatory factor 1 and -
2 (USF-1, USF-2) is a critical step in hormone activation of CD transcription in human
breast cancer cells. In contrast, CD is secreted constitutively in ER(a)negative cell lines.
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The mechanism by which IGF-II inhibits apoptosis is not well known. Apoptosis
is an essential physiological process for the selective elimination of cells; moreover
impaired apoptosis is a crucial step in tumorigenesis that endows neoplastie cells with
multiple advantages. So, neoplastie progression reflects loss of normal apoptotic
mechanisms. The Bcl-2 family, which consists of anti- and pro-apoptotic members, is the
best characterized family involved in the regulation of apoptotic cell death. The anti-
apoptotic member Bcl-2 (B cell lymphoma 2) localizes in the mitochondrial membrane as
well as in the endoplasmic retieulum membrane and nuclear envelope. Bcl-2 prevents
apoptosis either by sequestering caspases preforms or by preventing the release of
mitochondrial apoptogenic factors such as cytochrome e and AIF (apoptosis-inducing
factor) into the cytoplasm (15-17). In MCF-7 cells Bcl-2 levels can be modulated by
estradiol (E2) (18,19). These data suggest a potential link between estrogen, Bcl-2, and
estrogen mediated IGF-II in the inhibition of apoptosis in breast cancer cells.
Another potentially relevant inhibitor of apoptosis is Survivin, a member of the
inhibitor of apoptosis proteins family (lAPs) whose overexpression has been consistently
associated with inhibition of cell death initiated by both the extrinsic and intrinsic
apoptotic pathways (20, 21). Survivin is strongly and diffusely expressed in embryonic
and fetal organs, and overexpressed in a variety of tumors including breast carcinomas.
Survivin is known to bind directly to and inhibit caspase -3 and -7 (20), and its mRNA
and protein levels can be downregulated by the tumor suppressor p53 (which is also
linked to IGF-II regulation).
In recent years, RSV has gained considerable attention due to its potential as a
ehemotherapeutic agent for breast carcinomas. Although several reports have shown that
RSV displays a biphasic effect on breast cancer cell growth, proteins involved in the
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biphasic response and risks associated with RSV usage remain mostly unknown. The
studies conducted in this dissertation demonstrate that RSV could increase the risk of
breast cancer growth at low concentration by increasing proIGF-II levels. ProIGF-II not
only exerts its mitogenic effect in an autocrine/paracrine manner, but also by inducing
CD secretion and up-regulating the anti-apoptotic proteins Bcl-2 and survivin.
The study described in this dissertation evaluates the following specific aims: (1)
Determine RSV modulation of breast cancer cell growth in estrogen receptor positive and
negative cells. (2) Identify the effect of RSV on IGF-II expression in breast cancer cells;
(3) Determine whether IGF-II mediates RSV effects on breast cancer cells; (4) Identify
IGF-II regulated targets involved in breast cancer cell modulation - i.e. genes involved in
the apoptotic pathway and Cathepsin D (CD), an estrogen regulated protein associated
with breast cancer cell growth and released under the influence of IGF-II.
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CHAPTER TWO
REVIEW OF THE LITERATURE
Resveratrol
Structure and Function
Resveratrol (RSV) 3,5,4' trihydroxystilbene, is one of a group of compounds that
are produced by plants in times of environmental stress (Derks and Creasy, 1989). RSV
has been found in at least 72 plant species, a number of which are components of the
human diet, such as grapes, peanuts and mulberries (Derks and Creasy 1989). Grape skin
contains about 50-100 pg/gr of RSV (Jeandet et al. 1991). RSV synthesis ffomp-
coumaryl CoA and malonyl CoA is induced by stress, injury, infection or UV-irradiation.
RSV exhibits structural similarity with the synthetic estrogen diethylstilbestrol
(DES), and like stilbenes or triphenylethylenes, it exists as geometric isomers [the (E)- or
trans-isomer and the (Z)- or cis isomer]. These two isoforms may differ in their
scavenging, estrogenic or anti-estrogenic activities; moreover, these two geometrical
isomers are present in the human diet (Basly et al. 2000).
RSV exact physiological function is not known, but in plants it may have roles
protecting them against fungal infections and in conferring disease resistance. One of its
richest sources is the herb Polygonum cuspidatum, which has been used in Asian folk
medicine (Soleas et al. 1997). RSV exerts antioxidant and anti-inflammatory activities,
induces phase 11 drug-metabolizing enzymes (CYPlAl, CYP2A6, and CYP3A4), and it
is able to inhibit cyclooxygenase activity and transcription; thus it has multiple effects on
cellular events associated with carcinogenesis (Jang et al. 1997). It may also have in vivo
activities in modulating indices of platelet aggregation and lipid metabolism, which could
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explain the epidemiological evidence that RSV decreases coronary heart disease
mortality (Soleas et al. 1997). RSV has also been shovm to have growth inhibitory effect
in several human cancer cell lines and in animal models for carcinogenesis (Jang et al.
1997, Carbo et al. 1999, Tessitore et al. 2000). In HL60 promyelocytic leukemia cells,
treatment with RSV led to growth inhibition, induction of apoptosis, S-G2 phase cell
arrest, and myelomonocytic differentiation (Clemment et al. 1998, Ragione et al. 1998).
RSV also displayed antiproliferative effect in JB6 mouse epidermal, CaCo-2 colorectal
and A431 epidermoid carcinoma cell lines (Huang et al. 1999, Schneider et al. 2000,
Ahmad et al. 2001). RSV effects in breast cancer cells lines are more complicated.
Whereas some investigators have demonstrated antiproliferative effects in the MDA-MB-
231, KPC-l, MKL-F, T47D and MCF-7 cell lines (Clemment et al. 1998, Mgbonyebi et
al. 1998, Nakagawa et al. 2001), others have demonstrated growth enhancement in T47D
and MCF-7 cells (Gehm et al. 1997, Basly et al. 2000). The latter effect appears to be due
to the potential estrogenic effects of RSV. However, the precise mechanisms by which
RSV exerts these antitumor effects are not well known. Limited epidemiological and
clinical evidence suggest that RSV is well tolerated during human consumption and that
it may offer benefits with respect to atherosclerotic heart disease (Goldberg et al. 1996,
Pace-Asiak et al. 1996). Although RSV is available commercially as a dietary
supplement, there are no published controlled clinical studies demonstrating either its
efficacy or safety in the treatment or prevention of cancer or coronary artery disease.
RSV-Estrogen Receptor (ER) Interactions
RSV has been categorized as a phytoestrogen based on its ability to bind and
activate the ERa (Gehm et al. 1997). More recent data have shown that RSV also binds
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to a second subtype of ER, the ERP (Bowers et al. 2000, Bhat and Pezzuto 2001).
However, in contrast to other phjdoestrogens, e.g., genestein and coumestrol, which bind
with greater affinity to ERP than ERa (An et al. 2001, Kuiper 1998), RSV binds both ER
subtypes with similar affinity (Bowers et al. 2000) or with only a small preference to
ERp (Bhat and Pezzuto 2001). The effect(s) of RSV on breast cancer cell growth and ER-
mediated activation of gene transcription remain controversial; Gehm (1997) found that
RSV stimulated growth of the estrogen-dependent breast cancer cell line T47D, and that
the stimulation was blocked by the estrogen antagonist ICI 182,780. Other researchers
have reported that RSV decreases cell proliferation of both ER-positive and ER-negative
breast cancer cells (Damianaki et al. 2000, Lu and Serrero 1999, Mgbonyebi et al. 1998),
which suggests that the interaction of RSV with the ER may not fully explain its
inhibitory effect on proliferation.
RSV has both, estrogenic and anti-estrogenic properties when bound to the ER
and therefore has characteristics similar to the selective ER modulators (SERMs),
(Mizutani et al. 2000, Wu et al. 2001, Levenson and Jordan 1999). It has also been
shown that RSV acted as a mixed agonist/antagonist in different mammary cancer cell
lines in the absence of estradiol (E2), but in the presence of E2, RSV functioned as an anti-
estrogen.
RSV seems to act like a type I estrogen (estrogens that are sealed into the ligand-
binding domain of the ER) whose agonist actions are amplified through a synergistic
interaction of activation function (AF) -1 and -2 (Levenson et al 2003).
ERa-positive MCF-7 cells exhibited apoptotic cell death after RSV treatment,
while ERa-negative MDA-MB-231 cells did not (Pozo-Guisado et al 2004), suggesting
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that induction of apoptosis by RSV in human breast cancer cells could be ERa-mediated.
In vascular endotbelial cells, RSV was able to activate a rapid non-genomic
(membrane initiated) activation of ERa and ERp with consequent stimulation of
pbospborylation pathways (Klinge et al. 2005). These effects are mediated by the IGF-IR
pathway (Zhang et al, 2004).
Insulin-Iike Growth Factors
Insulin-like growth factors (IGFs) formerly known as somatomedins, are single
chain polypeptides that have mitogenic or growth promoting properties and have
structural similarity with pro-insulin (Sara and Hall 1990, Rosenfeld et al. 1990). IGF-I
and IGF-II share 62 % homology in their amino acid sequences. The mature IGF-I and
IGF-II peptides consist of a and p domains that are homologous to the a and p chains of
pro-insulin. Unlike insulin, the IGF peptides remain linked in the mature peptides by C
domains. Both, IGF-I and IGF-II contain an additional short D domain that is not foimd
in insulin. The IGF-I and IGF-II prohormones contain a C-terminal E peptide that is
cleaved in the Golgi apparatus during secretion (Daughaday and Rotwein 1989).
Insulin-like Growth Factor-I (IGF-I)
The IGF-I gene is located on chromosome 12; it consists of six exons and has two
promoter sites (Jansen et al. 1983, Tobin et al. 1990). The results of a series of studies
conducted in animal models, suggested that diet and nutrition might induce different
patterns of IGF-I transcripts (Pell et al. 1993, Zhang et al. 1997). Translation of pre-pro-
IGF-I can be initiated from codons in exons 1, 2 or 3; alternate polyadenylation sites in
the 3'-untranslated region of the molecule also contributes to differences in transcript
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size. IGF-I transcripts range in size from < 1 kb to 7.5 kb (Adamo et al. 1993).
Alternative splicing of the IGF-I gene product generates three different proIGF-I proteins.
These three forms contain 35 to 77 amino acid E-domains, which share a common 16
amino acid N-terminal portion.
Expression of the IGF-I gene is regulated primarily by growth hormone (GH).
Nevertheless, expression of IGFs is also influenced by various hormones, including
estrogens, adrenocorticotropic hormone, thyrotropin, luteinizing hormone, follicle-
stimulating hormone (FSH), as well as by other growth factors, such as platelet-derived
growth factor (PDGF), epidermal growth factor (EGF) and fibroblast growth factor
(FGF) (Pell et n/1993, Daughaday and Rotwein 1989, Stewart and Rotwein 1996). Diet
and nutrition affect circulating IGF-I levels, suggesting a possible role in IGF-I
production (Daughaday and Rotwein 1989).
IGF-I has both, immediate and long-term effects on various cellular activities, and
these effects are mediated mainly through the IGF-I receptor (IGF-IR). IGF-I exerts an
acute anabolic action on protein and carbohydrate metabolism by increasing cellular
uptake of amino acids and glucose, and by stimulating glycogen and protein synthesis
(Jones and Clemmons 1995). IGF-I also has a long-term impact on cell proliferation,
differentiation, and apoptosis (Jones and Clemmons 1995). IGF-I is a potent mitogen for
a wide variety of cells and exerts its mitogenic action by increasing DNA synthesis and
by stimulating the expression of cyclin Dl, which accelerates progression of the cell
cycle from Gi to S phase (Furlanetto et al. 1994, Dufoumy et al. 1997). The mitogenic
effect of IGF-I can be abolished by suppressing the expression of cyclin Dl (Kormann et
al. 1998). In addition to stimulating cell cycle progression, IGF-I also inhibits apoptosis.
IGF-I is able to stimulate the expression of Bel proteins and to suppress expression of
23
Bax, which results in an increase in the relative amount of the Bel/Bax heterodimer,
thereby blocking initiation of the apoptotic pathway (Minshall et al. 1997, Parrizas and
LeRoith 1997, Wang.et a/. 1998).
Insulin-like Growth Factor-II (IGF-II)
The IGF-II gene is located on chromosome 1 lpl5, 1.4 kb downstream from the
insulin gene (Brissenden et al. 1984). The IGF-II gene consists of nine exons, and the
mature peptide is encoded by exons 7, 8 and 9. The IGF-II gene is transeribed from four
different promoters (P1-P4). During fetal development, IGF-II expression is much higher
than in the post-natal period or in the adult. A distinct pattern of promoter use correlates
with expression levels during development. In the fetus, promoters P2-P4 are active,
while after birth PI becomes dominant (Sussenback et al. 1993). The IGF-II gene has
parental allele-specific expression, thus it is referred to as an imprinted gene
(Giannoukakis et al. 1993). When loss of imprinting occurs, biallelic expression of IGF-
II results, ultimately leading to over-expression of this potent growth factor (Jarrad et al.
1995, Oda et al. 1997, Cui et al. 1998).
IGF-II gene expression is regulated by tumor suppressor genes such as p53, WTl
(Wilms' tumor gene) and GC factor (GCF) (Kitadai et al.1993, Zhang et al. 1996,
Toretsky and Helman 1996). mRNAs transcribed from P1-P4 promoters range in size
from 1.8 kh to 6.0 kb. DNA methylation (Wutz and Barlow 1998), histone acetylation
(Hu et al. 1998) and use of specific promoter sites (Vu and Hoffman 1994, Yun et al.
1998) are mechanisms that may control allele-specific transcription.
The IGF-II gene encodes a single transcript that results in a 156 amino acid
protein, including an 89 amino acid E-domain. ProIGF-II contains sites of 0-linked
24
glycosylation. ProIGF-II is converted to mature IGF-II by sequential cleavage after
amino acids 104 and 87. Differential glycosylation and cleavage within the E-domain can
therefore result in multiple proIGF-II isoforms.
Concentration of IGF-II in the blood is higher than IGF-I levels in humans of all
ages. In adults IGF-II levels vary between 400-600 ng/ml whereas IGF-I levels range
between 100-200 ng/ml. IGF-II has mitogenic and anti-apoptotic actions, and regulates
cell proliferation and differentiation. Disruption of IGF-II gene in mice resulted in
substantial growth retardation (DeChiara et al. 1990). IGF-II also stimulates the
differentiation of neuronal and muscle cells, and plays an important role as an angiogenic
factor (Volpert et al. 1996). IGF-II can suppress apoptosis of mammary epithelial cells
induced by serum withdrawal (Farrelly et al. 1999). It has recently been established that
this is achieved through phosphatidyl inositol 3 kinase (PI3K) and mitogen-activated
protein kinase (MAPK) signals that ultimately inhibit the activity of the pro-apoptotic
protein BAD (Gilmore et al. 2002).
Insulin-like Growth Factor Binding Proteins (IGFBPs)
The actions of IGFs can be modulated by interactions with a family of six insulin
like growth factor binding proteins (IGFBPs). Their ability to form complexes with IGFs
influences IGFs transport to membrane receptors and thus, also affects IGFs effects on
cell proliferation (McCusker and Clemmons 1992). IGFBP-1 to -6, share 40-60% amino
acid homology. All six IGFBPs have 16-18 conserved cysteine residues in the amino and
carboxy terminal regions. The binding affinities of the six IGFBPs are similar for IGF-I
and IGF-II (2-20 and 3-30 XlO^/mol, respectively) with the exception of IGFBP-6, which
has 20- to 70-fold higher affinity for IGF-II (Zapf 1995). The majority of circulating
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IGFs (>97%) are bound to IGFBPs, predominantly IGFBP-3, whieh has an affinity equal
to or greater than that of the IGF-IR (Clemmons et al. 1990).
The IGFBPs genes share a common structural organization, in which four
conserved exons are located within genes ranging from 5 kb (IGFBP-1) to more than 30
kb (IGFBP-2 and -5) (Baxter 1997). Exon 1 of the IGFBP gene family is shared by
several other genes encoding a variety of proteins, leading to proposals that they might be
members of a larger gene family (Hwa et al 1999, Vilmos et al. 2001).
IGFBP-1
The IGFBP-1 gene is located on chromosome 7pl2-13, and is 5.2 kb in length.
IGFBP-1 is a 25 kDa protein with an Arginine-Glyeine-Aspartic Acid (RGD) sequence in
it carboxy terminus (Shimasaki and Ling 1991). The RGD sequence is recognized by
human integrin receptors in the cell membrane, suggesting an IGF-independent role
through these integrin receptors (Ruoslathi and Pierschlaber 1987). IGFBP-1 is produced
in the liver, decidua, and kidneys and is the most abundant IGFBP in amniotie fluid.
Insulin and eorticosteroid regulate IGFBP-1 levels in serum by transeriptional control of
hepatic sjmthesis (Hasegawa et al. 1995).
IGFBP-2
The IGFBP-2 gene is located on chromosome 2 (Allander et al 1993), and is 32
kb in length (Ehrenborg et al. 1991). IGFBP-2 is a 31 kDa protein (Shimasaki andLing
1991) that also has an RGD sequence, but IGFBP-2 has not been demonstrated to bind
integrin-type receptors.
IGFBP-2 concentrations are age-dependent, with the highest levels see during
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infancy and old age, and the lowest levels seen in young adults (Cohen et al. 1995).
IGFBP-2 is the primary IGFBP in cerebrospinal fluid (Bemardini et al. 1994) and is
elevated in certain tumors of the central nervous system. (Muller et al. 1994).
Additionally, IGFBP-2 expression is less dependent on insulin and the metabolic rate as
compared to IGFBP-1.
IGFBP-2 is the most abundant IGFBP secreted by estrogen receptor positive
breast cancer cell lines, and its secretion by breast tumors in vivo correlates with estrogen
receptor positivity (Maxwell et al. 1999). Our laboratory has previously reported IGFBP-
2 in the conditioned media from MCF-7 cells as well as IGFBP-2 mRNA (DeLeon et al.
1990).
IGFBP-3
The IGFBP-3 gene is located on chromosome 7 next to the IGFBP-1 gene
(Allander et al. 1993), and is 8.9 kb in length. IGFBP-3 serum levels are low at birth,
increase during childhood, peak at puberty, and decrease after puberty (Katz et al. 1995).
In vivo, GH is the primary regulator of IGFBP-3 expression (Katz et al. 1995), while in
vitro, IGFBP-3 can stimulate or inhibit growth in either an IGF-dependent or IGF-
independent manner (Murphy et a/. 1995, Nickerson et a/. 1998).
IGFBP-4
The IGFBP-4 gene is located on chromosome 17 (Allander et al. 1995). The non-
glycosylated form of IGFBP-4 has a molecular weight of 24 kDa, while the glycosylated
form weights 28 kDa (Katz et al. 1995). IGFBP-4 has been purified from many sources,
which include human osteosarcoma (Mohan et al. 1989, Andress and Bimbaum I99I),
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human prostatic carcinoma (Perkel et al. 1990), and human glioblastoma (Camacho-
Huber et al. 1992). In bone, IGFBP-4 is regulated by vitamin D and PTH (Mohan et al.
1995, Seharla et al. 1991).
Like IGFBP-2, elevated IGFBP-4 expression in leukemie T cells is affected by
the autocrine/paracrine aetion of IGF-II, but not by IGF-IR expression (Elminger et al.
1998). Overexpression and protein secretion of IGFBP-4 has been reported in breast
caneer cells (De Leon et al. 1990, Adamo et al. 1992). Yet unlike IGFBP-2, IGFBP-4
expression in breast eancer does not correlate with estrogen receptor status, sinee both
ER-positive and ER-negative eells secrete IGFBP-4 (Maxwell et al. 1993, Oh et al.
1996).
IGFBP-5
The IGFBP-5 gene is located on ehromosome 2, and its moleeular weight ranges
from 29 kDa to 32 kDa depending on glyeosylation status. In smooth muscle eells,
IGFBP-5 interact specifically with two extracellular matrix proteins (ECM),
thrombospondin-1 and osteopontin, whieh not only potentiate the IGF-I effeet but may
modulate the eooperative interaetion between the IGF-IR and integrin reeeptor pathways
(Nam et al. 2000). IGFBP-5 is thought to act as a depot for IGF-II in bone via its high
affinity for ECM proteins and hydroxy apatite, the mineral eonstituent of bone, and
potentiates the proliferative aetions of IGF-II on osteoblastie cells (Bautista et al. 1991,
Miyakoshi et al. 2001).
IGFBP-6
The IGFBP-6 gene is loeated on ehromosome 12, and the G-glycosylated protein
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weights 34 kDa (Allander et al. 1993, Cohen and Rosenfeld 1995). Human IGFBP-6 is
primarily found in CSF and serum (Katz et al. 1995). IGFBP-6 is the only IGFBP that
has higher affinity for IGF-Il than for IGF-1 (Baxter et al. 1992, Bach et al. 1993,
Clausen et al. 1995). lGFBP-6 expression is regulated by lGF-11. Furthermore, only
estrogen receptor-negative breast carcinoma cell lines produced IGFBP-6. In these breast
carcinoma cell lines, IGFBP-6 expression was enhanced by retinoic acid, but was not
affected by IGF-I (Shiekh et al. 1993).
IGF Receptors
Both, the IGF-I and IGF-II receptors are glycoproteins that are located on the cell
membrane. The two receptors, however, differ completely in structure and function
(LeRoith et al. 1995, Stewart and Rotwein 1996).
IGF-I Receptor (IGF-IR)
The IGF-IR gene is located on chromosome 15p25-26, it has a size of 100 kb, and
consists of 21 exons. IGF-IR is a tetramer of two identical a-subunits (706 amino acids)
and two identical P-subunits (626 amino acids) (Stewart and Rotwein 1996, Sepp-
Lorenzino 1998). The a-subunits are extracellular and form the ligand-binding domain.
The two P-subunits, which contain short extracellular and transmembrane segments and a
larger intracellular segment, transmit the ligand-induced signal. The p-subunit has three
domains: a tyrosine kinase domain; a juxtamembrane domain, which has motifs required
for recruiting the major signaling adapter proteins, like insulin receptor substrate (IRS)
and Src/collagen homology proteins (SHC); and the carboxyl terminal domain, which has
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several important residues for IGFs signaling. These residues in the carboxyl-terminal
domain are required for binding various signaling proteins, like growth faetor receptor-
bound protein 10 (Grb-10), 14-3-3-epsilon (Ogihara et al. 1997), p85 subunit of
phosphatidyl inositol 3' kinase (PI3K), and SHPTP2 (Hongo et al. 1996, Sepp-Lorenzino
1998). Specific residues of the IGF-IR, which mediate mitogenesis, transformation and
anti-apoptotic functions of the IGFs, that are important for malignant phenotype have
been identified (Miura et al. 1995, O'Connor et al. 1997).
When IGF-I or IGF-II binds to the extracellular subunit of the IGF-IR, a
conformational change is induced in the transmembrane P-subunits, resulting in
autophosphorylation of the eytoplasmie tyrosine kinase domain of the P-subunit. This
fully activates the receptor tyrosine kinase, which then autophosphorylates additional
tyrosine residues in the juxtamembrane and carboxyl-terminal domains flanking the
tyrosine kinase domain. These phosphorylated residues (particularly tyrosine 950), can
then function as docking sites for the IRS and She adaptor proteins. Phosphorylation of
these adaptor proteins allows them to recruit other factors, such as Grb/SOS and the p85
regulatory subunit of phosphatidyl inositol 3' kinase (PI3K), thereby leading to activation
of the (mitogen activated protein) MAP kinase and PI3K cascades. The ultimate targets
of the MAPK and PI3K pathways include members of the Ets and forkhead transcription
factors families. Regulation of transcription factors provides a mechanism by which IGF
action at the cell surface can elicit changes in gene expression that eventually mediate the
proliferative, differentiation, and apoptotie effects of IGFs (LeRoith et al. 1995).
IGF-II Receptor (IGF-IIR or M6P/IGF-IIR)
The IGF-IIR gene is located on chromosome 6q25-27, and is 140 kb in size. The
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IGF-IIR is monomeric (Morgan et al. 1987, Oshima et al. 1988, Gates et al. 1998).
Three ligand-binding regions are found in the extracellular domain of the receptor, one
for IGF-II binding and two for protein containing mannose-6-phosphate (M6P), including
renin, proliferin, thyroglobulin, and the latent form of transforming growth factor (TGF)-
P (Jones and Clemmons 1995). Binding of the IGF-IIR to TGF-P activates the latter
(Gates et al. 1998, Braulke 1999). Since IGF-IIR can bind both, IGF-II and M6P-
containing molecules, it is also called the IGF-II/M6P receptor. The IGF-IIR is also
involved in targeting of proteins to the lysosomes and may play a role in degradation of
the extracellular matrix. There is also some evidence that interactions of IGF-IIR with
mannose 6-phosphate-bearing proteins may increase breast tumor angiogenesis
(Rasmussen and Cullen 1998). Although the binding sites for lysosomal enzymes and
IGF-II are distinct, reciprocal inhibition between the ligands has been observed (Kiess et
al. 1989). When M6P proteins bind, IGF-II binding is decreased, possibly due to steric
hindrance or conformational changes in the IGF-IIR (Vignon and Roehefort 1992). In
MCF-7 cells an extracellular reciprocal interaction exists between IGF-II and Cathepsin
D at the IGF-IIR. IGF-II inhibited 55% of '^^I-eathepsin D binding to the IGF-IIR
(Mathieu et al. 1990). Little is known about the regulation of IGF-IIR expression,
although some studies have suggested that insulin, IGFs, EGF, and M6P may increase the
level of IGF-IIR in the cell membrane (Jones and Clemmons 1995, Stewart and Rotwein
1996, Hoeflich et al. 1996, Takigawa et al. 1997). IGF-IIR has no tyrosine kinase
activity, and since binding of IGF-II to the IGF-IIR results in degradation of IGF-II,
IGF-IIR acts like an antagonist to IGF-II, reducing its biological activity (Gates et al.
1998). Because of this effect, IGF-IIR has been considered to be a potential tumor
suppressor molecule. A unique feature of the IGF-IIR may contribute to its ability to act
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as a scavenger for eireulating IGF-II: upon proteolytic eleavage, the extraeellular domain
of the reeeptor is dissociated from the cell membrane as a soluble fragment that cireulates
in the blood with the ability to bind to IGF-II and to faeilitate its degradation (Kiess et al.
1987, MacDonald et al 1989, Valenzano et al 1995, Zaina and Squire, 1998, Costello et
al 1999). Under normal physiological conditions, there is an equilibrium and rapid
movement in the eycling of the IGF-llR between the cell surface and internal organelles.
However, abnormalities anywhere in the traffieking may have major eonsequences in
normal cellular function and organism survival. In the human lysosomal storage disorder
(L eell disease), a deficiency in the enzyme N-acetylglueosamine phosphotransferase
usually results in the death of the affeeted person as a result of the inability of hydrolases
to be traffieked to lysosomal eompartments (Storrie and Desjardins 1996). However, this
defective-traffieking disorder is not associated with an increased rate of malignancy.
Since malignancy is not a characteristic of this disease, defective IGF-llR-mediated
trafficking of M6P proteins does not initiate malignant transformation, hut may
eontribute to tumor progression.
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Figure 1. High levels of IGF-II compete with cathepsin D (CD) for biding to the IGF-
II/M6P receptor. The IGF-II/M6PR binds both IGF-II and CD, which have separate
binding sites. It targets lysosomal enzymes to lysosomes and also functions in the control
of extracellular IGF-II levels. (I) Competition of both ligands in the Golgi; (2) IGF-II
inhibition of CD uptake at the extracellular level.
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Insulin Receptor (IR)
The IR gene is located on chromosome 19pl3.3-pl3.2. IR is a transmembrane
glycoprotein that mediates the pleiotropic actions of insulin. The homodimeric IR exists
in two isoforms that arise from the alternative splicing of exon 11 in the IR mRNA (Seino
and Bell 1989). Exon 11 codes for 12 amino acids (residues 717-728) that are inserted
upstream of the 3'^'^ last residue of the extracellular a-subunits of the IR-B isoform. The
IR-A (or IR exon 11-) isoform lacks these 12 amino acids. The presence or absence of the
exon 11 encoded peptide yields two receptors with unique biochemical properties.
Although both isoforms have similar affinity for insulin, the IR-A binds IGF-II with over
ten-fold higher affinity than the IR-B (McClain 1991, Yamaguchi et at. 1991, Frasca et
al. 1999). The two IR isoforms also display differential kinase activity (Kellerer et al.
1992). The IR-A isoform exhibits a more rapid interhalization and higher recycling rate
than the IR-B (Vogt et al. 1991). The isoforms localize to different regions of the plasma
membrane (Uhles et al. 2003).
The high affinity interaction of the IR-A with IGF-II (mediated through IGF-II C
and D domains), but not IGF-I, is important for normal fetal and cancer growth (Denley
et al. 2003). Mouse knockout models suggest that while the developmental growth-
promoting activities of IGF-I are exclusively mediated through the IGF-IR, IGF-II can
stimulate growth via not only the IGF-IR but also the IR (Louvi et al. 1997). Cancer cells
expressing the IR-A migrate and are protected from apoptosis by exposure to IGF-II but
not when exposed to the same level of IGF-I (Sciaeca et al. 2002). IGF-II is
overexpressed by many cancer cells such as breast cancer (Quinn et al. 1996), and
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colorectal cancer cells (Renehan et al. 2000), which also express the IR-A as the
predominant IR isoform.
In IGF-IR deficient murine fibroblasts transfected with the human IR-A, IGF-II
was a more potent mitogen than insulin (Frasca et al 1999). Similar findings were
observed in SKUT-1 human radbdomyosarcoma eells (which lack IGF-IR). In these cells
IGF-II was significantly more potent than insulin in stimulating the Shc/ERK pathway,
while insulin was more potent than IGF-II in stimulating the IRS-l/PDIC/Akt pathway.
As a result, IGF-II was more potent than insulin in inducing cell invasion, while insulin
was slightly more effective in apoptosis protection. IGF-II binds to the IR-A with high
affinity in both, human breast cancer cell lines and human breast cancer specimens,
stimulating the receptor tyrosine kinase activity and leading to mitogenesis. Moreover, in
certain breast cancers (MDA-MB-157 cells and node-negative breast cancers), IGF-II
predominantly signals via the IR rather than via the IGF-IR (Sciacca et al 1999).
Hybrid Receptors
The complexity of IGF signaling is increased by the formation of hybrid receptors
that result from the dimerization of IGF-IR and IR hemi-receptors. Each hybrid receptor
consists of a single a and P subunit linked by disulfide bonds, which are formed in the
Golgi apparatus of cells expressing both the IGF-IR and the IR. This could be due to the
preferential formation of disulfide bonds between cysteine residues in IGF-IR and IR
subunits themselves. Thus, in some circumstances, hybrid receptors may outnumber
homoreceptor molecules at the cell surface. Hybrid receptors retain high affinity for
IGFs, but exhibit a dramatically decreased affinity for insulin. Thus, the presence of a
significant number of hybrid receptors may selectively diminish cellular responsiveness
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to insulin, but not to IGFs. The effects of hybrid receptors are further complicated by the
presence of the IR-A and IR-B isoforms and their different IGF-II binding characteristics.
Therefore, the relative expression of the IGF-IR and IR genes and the degree of
alternative splicing of exon 11 of the IR gene governs the ability of a given cell to
respond to IGF-I, IGF-II, and insulin.
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Table 1. Molecular Features of Members of the IGF Family
Molecular No. of amino Gene














IGF-IIR 270 2450 6q25-6q27 140 48
IGFBP-1 25.3 234 7pl2-7pI4 5.2 4
IGFBP-2 31.4 289 2q3I-2q34 32 4




IGFBP-5 28.6 252 2q31-2q24 33 4
IGFBP-6 22.8 216 12qI3 4.7 4
Abbreviations used: IGF = insulin-like growth factor; IGFBP = insulin-like growth
factor-binding protein; IGF-IR = IGF-I receptor; IGR-IIR = IGF-II receptor; kb =
kilobases; kDa = kilodaltons.
tIGF-IR is a tetrameric protein (two «- and two 13-subunits).
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IGF-II, breast cancer and cell survival
Mechanisms ofIGF-II Over-expression and Preferential Promoter Usage
Increased levels of lGF-11 in the micro-environment of a tumor can be potentially
aecomplished by multiple mechanisms including: (1) loss of imprinting (LOl) where
lGF-11, whieh is normally expressed from the paternal allele, is now expressed from both
alleles, maternal and paternal (Ogawa et al. 1993, Rainier et al. 1993, Zhan et at. 1994);
(2) loss of heterozygosity (LOH) with paternal duplication, where lGF-11 transeription
oeeurs from two eopies instead of one eopy of a gene, leading to higher mRNA levels;
(3) Loss of transcriptional suppressors. A possible suppressor candidate could be the
Wilms' tumor-1 protein (WT-1). WT-1 protein has been shown to bind to sites within the
lGF-11 promoter-3 (P3), and decrease lGF-11 transeription (Drummond et al. 1992). The
tumor suppressor gene p53 may function to suppress lGF-11 activity through direct
inhibition of transcription (Zhang et al. 1996) or by induction of lGFBP-3 (Buckbinder et
al. 1995). Thus, mutations of p53, found in many tumors, may also contribute to
inereased lGF-11 expression. (4) lGF-11 over-expression may also occur through
excessive transcription due to the activation of transcription factors that positively
regulate lGF-11.
lGF-11 gene promoter activation is highly variable in malignant and benign breast,
prostate and bladder tissues. While a majority of tumor samples utilized three promoters,
P2-P4, in a variety of combinations, when quantitated, P3 and P4 promoters where much
more active than P2 (Mineo et al. 2000).
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IGF-II-Induced Malignant Transformation
Studies from transgenic mice over-expressing IGF-II, and IGF-II knockout mice
indicate that this growth factor plays an important role in normal biology and malignant
transformation of breast epithelial cells. Mice over-expressing IGF-II in the mammary
gland under the control of the sheep P-lactoglobulin promoter elements, showed
mammary tumor formation (Bates et al. 1995). Mice from four different transgenic lines
over-expressing IGF-II developed mammary tumors. While IGF-II over-expression does
not cause malignant tumor growth in some other organs such as uterus (Ward et al.
1994), in the mammary gland excess IGF-II contributes to tumor formation. This
provides evidence for the role of IGF-II signaling in malignant transformation.
In breast cancer, IGF-II is expressed in the stroma (Giani et al. 1996) but can also
be found in the malignant breast epithelial cells (Paik 1992). IGF-II plays a role in
malignant transformation, and is important in the maintenance of the malignant
phenotype. In addition, it has been shown that malignant breast epithelial cells can induce
expression of IGF-II in the stroma in vitro (Singer et al. 1995).
IGF-II and Cell Migration
Altered contact between cells and their associated extracellular matrix (ECM) is a
prerequisite for breast cancer cell migration and thus metastasis (Gui et al. 1997). Cell
migration requires interactions with adhesive molecules, such as vitronectin (VN);
indeed, interaction of cells with VN has been reported to be essential for IGF-stimulated
migration (Stewart et al. 1990, Jones et al. 1996, Doerr and Jones 1996, Clemmons et al.
1999). VN binds directly to IGF-II (Upton et al. 1999). IGF-II has been demonstrated to
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stimulate increased migration in breast carcinoma cells (Jones et al. 1996). One
mechanism through which this has been hj'pothesized to occur is by increased avp3-
integrin expression (VN receptor), thus facilitating an increased interaction with VN in
the ECM. Studies examining functional interactions between VN and the IGF system
demonstrate that VN and IGFs are tightly regulated and closely associated. This is
illustrated by demonstration that occupancy of both, the avPs-VN receptor and the IGF-
IR are prerequisites for cell cancer migration (Jones et al. 1996, Doerr and Jones 1996,
Zhang and Clemmons 1998), and by the finding that IRS-1, a downstream target of IGF-
IR, associates with the VN receptors, the av-integrins (Vuori and Roushlathi 1994).
The IGF-II-VN complex can stimulate migration of MCF-7 cells, this effect may
in part, be attributable to reduced interactions with the IGF-IIR (Noble et al. 2003).
IGF-II, Estradiol and Estrogen Receptor (ER) Interactions
IGF-IR and ER are co-expressed in some breast cancer cells, and there is a complex
crosstalk between the two pathways (Yee and Lee 2000). This crosstalk is of particular
importance to breast cancer since ER is known to be a strong prognostic factor for breast
cancer growth and anti-estrogens such as tamoxifen are widely used in treating the
disease. In vitro, ER-positive breast cancer cells (MCF-7, T47D and ZR-75) can be
stimulated to proliferate by pico- or nanomolar concentrations of IGF-II (Karey and
Sirbasku 1988), while ER-negative cells (MBA-MB-231, MDA-435) are only minimally
responsive or are not stimulated to proliferate by the IGFs. Furthermore, a synergy occurs
between estradiol and IGF-I in mediating the proliferative response in ER-positive cells
(Stewart et al. 1992). An explanation for this effect may be that the expression of nearly
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all members of the IGF system is under transcriptional control of the ER. Thus, the ER
regulates the transcription of IGF-I (Umayahara et al. 1994), IGF-II (Osbome et al. 1989,
Lee et al 1992), IGF-IR (Stewart et al 1992), IGFBPs (McGuire et al 1992) and IRS-1
(Lee et al 1999, Salerno et al 1999, Molloy et al 2000).
IGFs have also been reported to activate the ER. Estrogen is able to bind the ERa
in the cytosol, which then interacts with the adapter proteins She or p85a of PI3-kinase.
Both Shc/ER and PI3K/ER complexes can further form a ternary complex with IGF-IR
on the cell membrane, leading to translocation of the ER to the region of the cell
membrane and activation of the IGF-IR-dependent MAP-kinase or PI3K/Akt pathways
inducing cell proliferation and prevention of apoptosis (Zhang et al, 2004).
IGF-II and Apoptosis
Programmed cell death (PCD) or apoptosis, constitutes a system for the removal
of unnecessary, aged, or damaged cells that is regulated by the interplay of pro-apoptotic
and anti-apoptotic proteins.
Protection from apoptosis by IGFs is mediated by activation of PI3K and the
Akt/protein kinase B (PKB) pathway (Kulik et al 1997, Peruzzi et al 1999) Akt/PKB
phosphorylates BAD, a member of the Bcl-2 family of pro-apoptotic proteins (Datta et al
1997, 2000); phosphorylated BAD cannot heterodimerize with Bcl-2 or Bc1-Xl, remains
in the cytosol and does not promote cell death (Zha et al. 1996). It has been reported that
IGFs can also mediate their anti-apoptotic effect by other pathways that do not involve
BAD (Kulik and Weber 1998). Thus, IGFs can protect cells from apoptosis by multiple
signaling pathways.
The IGF-IIR also plays an important role in the IGF-II mediated effect on
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apoptosis. One study found cancer-related missense mutations in the IGF-IIR gene with
resultant disruption of the binding of IGF-IIR to its ligand. Cancer cells that lack the
ability to degrade IGF-II have been shown to have strong growth potency (Byrd et al.
1999). Suppressing the expression of IGF-IIR yields the same effect as mutation in the
IGF-IIR gene (CGorman et al 1999). Reestablishing the function of IGF-IIR in cancer
cells that lack IGF-IIR reduces cancer growth and increases apoptosis (Souza et al
1999).
IGF-II specifically, has been found to protect cancer cell from apoptosis induced
by different mechanisms. Endogenous or exogenous IGF-II addition to C2CI2 mouse
myoblasts caused protection from cisplatin-induced apoptosis. This effect was associated
with an increase in p70 ribosomal protein S6 kinase (p70S6K, which plays a critical role
in cell growth) basal activity (Wan and Helman 2002). IGF-II has also been shown to
induce a delay in mammary involution in vivo in the IGF-II transgenic mouse model. In
this study the delayed mammary involution resulted from a significant reduction in
mammary epithelial apoptosis, and not from increased cell proliferation. This effect
correlated with prolonged Akt/PKB phosphorylation. In a different study, IGF-II
significantly reduced retinoic acid (RA)-induced apoptosis of keratinocytes, whereas
IGF-I and insulin did not. The inhibition of RA action by IGF-II was independent of its
ability to signal through the IGF-IR or to interact with IGFBPs (Louafi et al 2003).
Cathepsin D and the M6P/IGF-IIR
The human Cathepsin D gene contains nine exons and is located in chromosome
1 lpl5 (Augereau et al 1988, Redecker et al 1991), and expresses a 2.2 kb transcript.
Cathepsin D is synthesized as preprocathepsin D (pCD). Upon entering into an acidic
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lysosome, the single chain proeathepsin D (52 kDa) is activated to CD (51 kDa) and
further processed and glycosylated into several distinct forms (51-14 kDa). For more
than a decade, over-expression and secretion of Cathepsin D (CD) by breast cancer cells
have been associated with increased risk of relapse and metastasis (Rochefort et al. 1987,
Thorpe et al. 1989, Spyratos et al. 1989). The mechanism by which CD increases the
incidence of clinical metastasis involves increased cell growth rather than escape of
cancer cells through the basement membrane. The fundamental role of CD is to degrade
intracellular and internalized proteins (Dingle et al. 1973). CD has been suggested to take
part in antigen processing (Williams and Smith 1993), and in enzjmiatic generation of
peptides hormones. CD is catalytically active at acidic pH values that vary according to
substrates, but is mostly found in intracellular vesicles, lysosomes, phagosomes and late
endosomes. CD is a lysosomal protease regulated by estrogens in ER-positive cells, but
secreted eonstitutively by ER-negative cell lines. The proportion of pCD secreted by
human breast cancer cell lines has been shown to correlate with their invasive potential
(Couissi et al. 1997). Normally, the newly synthesized soluble lysosomal enzymes, such
as pCD, are post-translationally modified to contain M6P residues on their N-linked
oligosaecharides. The acquired M6P residues enable the enzymes to bind to M6P
receptors (IGF-II/M6PR) in the Trans Golgi network (TGN). The receptors and their
ligands cluster into transport vesicles and travel to an acidic pre-lysosomal compartment
where the low pH causes dissociation of the receptor-ligand complex. The free M6P
receptors can travel to the plasma membrane or back to the Golgi to reinitiate another
cycle of biosynthetic enzyme transport. In the absence of M6P receptors, most M6P-
containing glycoproteins are secreted from the cell. The IGF-II/M6PR is mainly localized
in the intracellular compartments (90%), with 10% of the receptor being present on the
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MCF-7, T47D, Hs478t breast carcinoma cell lines and MCF-lOA breast epithelial
cells were obtained from the American Type Culture Collection (ATCC). MCF-7 cells
were maintained in a 5% C02 incubator at 37''C, using DMEM/F12 media (Cellgro)
supplemented with 10 ml of 5,000 units penicillin/streptomycin (100 units/ml penicillin
and 100 units/ml streptomycin sulfate, Cellgro), 4niM L-glutamine (Cellgro), 3 pg/ml P-
amphotericin, and 5% fetal bovine serum (Hyclone). T47D cells were grown in RPMI-
1640 media supplemented with 10 pg/ml insulin, 2mM L-glutamine (Cellgro), 5,000
units penicillin/streptomycin (100 units/ml penicillin and 100 units/ml streptomycin
sulfate, Cellgro) and 10% fetal bovine serum (Hyclone). Hs578t DMEM media was
supplemented with O.Olmg/ml bovine insulin (Sigma), 10% fetal bovine serum
(Hyclone), 4niM L-glutamine (Cellgro) and 10 ml of 5,000 units penicillin/streptomycin
(100 units/ml penicillin and 100 units/ml streptomycin sulfate, Cellgro). MCF-10
DMEM/F12 media was supplemented with 10 ml of 5,000 units penicillin/streptomycin
(100 units/ml penicillin and 100 units/ml streptomycin sulfate, Cellgro), 4mM L-
glutamine (Cellgro), 3 pg/ml P-amphotericin, 10 pg/ml insulin (Sigma), 0.5 pg/ml
hydrocortisone (Sigma), murine epidermal growth factor (EGF) 20 ng/ml (GIBCO-BRL),
cholera toxin lOOng/ml (Sigma) and 5% equine serum. Cells were detached by
trypsinization (Ix Trypsin EDTA, Cellgro). Recombinant human precursor lGF-11
(prolGF-11, aa 1-156) was purchased from GroPep (Adelaide, Australia). Resveratrol was
purchased from Sigma Chemical Co. (St. Louis, MO), and dissolved in dimethyl
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sulfoxide (DMSO, Fischer Scientific, Pittsburgh, PA). Media from RSV treated cells
(CM) was collected (24 and 48 hrs), centrifuged (800 rpm for 5min) and frozen (-20®C)
until assayed. Cell lysates from RSV treated cells (CL) was collected, (3, 6 hrs),
centrifuged (800 rpm for 5min), and frozen (-20'^C) until assayed.
Western blot analysis
Total protein concentration (30 pg) of serum free medium (SFM) collected after
24 and 48 hrs of RSV treatment (10"^-10"'^) and control group (SFM with vehicle) or (3-5
pg) of cell lysates collected after 3 and 6 hrs of RSV treatment, was used to load 10-20%
polyaerylamide-SDS gradient gels and transferred to a nitrocellulose membrane Bio-
Trace'^NT (Life Sciences, Ann Arbor, MI) using a Semi-Dry electrophoretic Transfer
Cell (Bio-Rad Laboratories, Hercules, CA). Protein concentration was measured using
the Coomassie Plus Protein Assay Reagent^"^ (Pierce Biotechnology, Rockford,IL)
Nitrocellulose membranes were blocked with 2% BSA IgG free (Sigma Chemical Co.,
St. Louis, MO) in PBS/0.05% Tween for 2 hrs. Membranes were then incubated with
Amano IGF-II monoclonal antibody, clone S1-F2 (1:1000 Amano, Mitsubishi, Troy,
VA). The Amano antibody is able to detect both the mature and the precursor forms of
IGF-II. Similarly, the IGF-I polyclonal antibody (1:1000, Oncogene Research Products,
San Diego, CA) was used to detect IGF-I. Cathepsin D antiserum (1:400) was used to
detect CD immunoreactive bands. Membranes were also incubated with anti-Bcl-2
monoclonal antibody (Santa Cruz Biotechnology, CA), anti-survivin polyclonal antibody
(Novus Biologicals, Littleton, CO), and incubated at 4'^C overnight. The blots were also
probed with P-actin antibody (1:10,000, Sigma Chemical Co., St. Louis, MO) and used as
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a protein loading control. After 3x10 min washes in PBS/0.05% Tween, the
corresponding secondary antibodies (1:1000, Amersham, Arlington Heights, IL) were
added to the membranes (1 hr at RT), followed by 3 x 10 min washes and HRP (1:1000
Amersham, Arlington Heights, IL). Protein visualization was achieved by using enhanced
chemiluminescence (ECL) and autoradiography with Hyperfilm ECL film (Amersham,
Arlington Heights, IL). The signals on the x-ray films were quantified using
Chemilmager™ 4000 (Alpha Innotech Corporation).
Northern blot analysis
Total RNA was extracted using Tri Reagent™ (Molecular Research Center), after
12 and 24 hrs incubation of MCF-7 and MCF-IOA cells in serum free media (SFM), in
the presence of 10'^ or lO'"^ M RSV. RNA was then precipitated using isopropanol and
solubilized in 0.5% SDS. 10 pg of each sample RNA was then electrophoresed on a 1%
agarose-formaldehyde gel, and transferred to a nylon membrane (Hybond™-N,
Amersham, Arlington Heights, IL) followed by UV cross-linking. The membranes were
pre-hybridized (Clontech expressHyb™ solution) for 1 hr at 68®C, before ̂ ^P-labeled
IGF-II cDNA or CD cDNA was added. Blots were hybridized at 42''C. The membranes
were then washed and exposed to Kodak film with intensifying screens at -SO^'C for 2-3
days. Subsequently, the membranes were stripped and reprobed with ̂ ^P-labeled
cyclophilin cDNA, which was used as a loading control. The signals were quantitated




Cell growth was measured by bromodeoxyuridine (BrdU) incorporation assay
(Oneogene Research Products, San Diego CA), after 24 and 48 brs of RSV treatment.
MCF-7 cells (IxlO'^/well) were plated in 96 well tissue culture plates and grown in serum
free medium (SFM). After 6 brs incubation, 10"^ M or 10""* M RSV was added to the
wells.
Cells were then incubated with BrdU label for 20 brs (5% CO2, 37^C incubator). BrdU
incorporation was detected immunocbemically, following partial denaturation of double
stranded DNA. In this assay, borseradisb-peroxidase (HRP) catalyzes the conversion of
the cbromogenic substrate tetra-metbylbenzidine (TMB) to a blue solution, the intensity
of which is proportional to the amount of incorporated BrdU in the cells. The colored
reaction product is then quantified using a spectropbotometer (405-595 nm). To evaluate
at what extent the concentration-dependent effect of RSV on cell growth was due to IGF-
II, BrdU incorporation was measured in the presence of 2 pg/ml anti-IGF-IR antibody
(Santa Cruz Biotechnology), which inhibits binding as well as basal and IGF-I / IGF-II
stimulated DNA synthesis. The effect of different concentrations of proIGF-II (10-
lOOng/ml) on RSV (10""^ M) treated MCF-7 cells was also assessed by BrdU
incorporation, after 24 and 48 brs.
Cell viability assay
Cell viability was measured by the 3-[4,5-dimetbyltbiazol2-yl]-2,5-
dipbenyltetrazolium bromide (MTT) assay; cells (IxlO'^/well) were seeded in 96 well
plates, and grown in serum free medium. Cell viability (MCF-7, MCF-10, T47D and
Hs578t cells) was assessed at 24 and 48 brs, by measuring the rate of tetrazolium salts
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reduction to formazan (MTT, Sigma Chemical Co., St. Louis MO), which is proportional
to the number of living cells. At the end of incubation, the absorbance was read at 540
nm. To evaluate at what extent the concentration dependent effect of resveratrol on cell
survival is due to proIGF-II signaling through the IGF-IR, parallel wells containing
MCF-7 cells treated with 10"^ M RSV, were incubated simultaneously with 2 pg/ml of
anti-IGF-IR antibody. Cell viability was also measured in MCF-7 cells (IxlO^'/well)
transfected with the mature or the precursor form of IGF-II were seeded in 96 well plates,
and grown in serum free medium. Cell viability was assessed at 24 and 48 hrs, by
measuring the rate of tetrazolium salt reduction to formazan (MTT, Sigma Chemical Co.,
St. Louis MO), which is proportional to the number of living cells. At the end of
incubation, the absorbance was read at 540 nm.
Cathepsin D antibodies
Cathepsin D was purified from human placenta according to the method of Takahashi
and Tang, except that a Concanavalin A-Sepharose column purification step was used
before affinity chromatography on Pepstatin-Sepharose. Analysis of protein purity by
sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/PAGE) confirmed the
presence of a major band of 30 kDa and a minor band of 14 kDa (visualized by silver and
Coomassie blue staining of the gel) Two rabbits (# 4607 and 4608) were immunized with
this preparation of Cathepsin D. Sera was collected and titered by immunoprecipitation of
Cathepsin D as described by our laboratory.
Construction of vectors
The human IGF-II (cDNA) was kindly provided by Dr. Graeme I Bell (Howard
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Hughes Medical Institute, University of Chicago). The sense precursor IGF-II was
generated by PGR and cloned into the HindOl-Xbal site of the pRc/CMV vector
(Invitrogen, San Diego, CA) as previously detailed (DeLeon et al, 1999).
Transfection ofMCF-7, Hs578t and MCF-1 OA cells with IGF-II sense cDNA
MCF-7, Hs578t and MCF-lOA cells were transfected with the sense IGF-II
vector. Transfection was carried out by the liposome method (DOTAP, Boehringer).
G418 (Geneticin, 560 pg/ml) was used to maintain stable transfectants, which were
cloned by limiting dilution in 96 well plates. To identify sense clones, serum-free CM
from 96 well plates was screened with a dot blot assay, which measures IGF-II without
interference by IGF binding proteins (DeLeon et al, 1997).
Real Time PGR
One Step SYBR real-time RT-PCR was performed to assess Bcl-2 and survivin
expression in RSV (10""^) treated cells, using the following primers: Bcl-2-F (ATG TGT
GTG GAG AGC GTC AAC C-3'), Bcl-2-R (AGC GAG GAG AAA TCA AAC AGA
GG-3'), survivin-F (TCA AGG AGC AGC GGA TGT GTA G-3'0, survivin-R (TGA
AGC AGA AGA AAC ACT GGG G-3') PGR amplifications were performed using the
iCycler (BIO-RAD). Reactions were performed in a mixture consisting of a 50 pL
volume solution containing IX SYBR Green supermix PGR buffer (BIO-RAD),
{lOOmM KGL, 6 mM MgG12,40mM Tris-HGL, PH 8.4, .4mM of each dNTP (dATP,
dCTP, dGTP and dTTP), iTaq DNA Polymerase 50 U/mL, SYBR Green I, 20mM
Fluorescein,} 300 nM of each primer, 0.25U/mL MultiScribe Reverse Transcriptase
(Promega) and 0.4U/mL Rnase Inhibitor (Promega). The RT-PGR protocol starts with 30
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min at 42°C for the RT. Prior to the PGR step, iTaq DNA polymerase activation at 95 °C
for 10 min was performed. Followed by 30 s denaturation at 95 °C, 15 s annealing at 57
°C and 1.5 min elongation at 72 °C for 40 cycles. Fluorescence was detected at the end of
every 72°C extension phase. To exclude the contamination of unspecific PGR products
such as primer dimers, melting curve analysis was applied to all final PGR products after
the cycling protocol.
Caspase activation assay
MGF-7 cells (IxlO"^ cells/well) were seeded in 96 well plates and incubated
overnight at 37 ̂C. The following day RSV (lO""* M) alone or in combination with IGF-II
(mature or precursor forms, 100 ng/ml) was added to the cells for 3 or 6 hrs, followed by
addition of 50 pi of caspase assay buffer (150mM HEPES, 450 mM NaGl, 150 mM KGl,
30 mM MgGli, 1.2 mM EGTA, 1.5% Nonidet P40,0.3% GHAPS, 30% sucrose, 150 pM
DEVD-AMG, 30 mM DTT, 3.0 mM PMSF). Gaspase activity was measured by reading
proteolytically released fluorochrome from the DEVD-AMG substrate using a plate
reading fluorometer with an excitation at 360 nm and an emission at 460 nm.
Mitochondrial membrane potential assessment using JC-1
JG-1 was used for the investigation of mitochondrial membrane depolarization that
occurs in the initial stages of apoptosis. JG-1 is a lipophilic fluorochrome (5,5',6,6'-
tetrachloro-l,r,3,3'-tetraethyl benzimidazol carbocyanine iodide) that stands for 1st J-
aggregate-forming cationic dye found to be sensitive to the Av|/. The fluorescence
emission spectrum of JG-1 is dependent on its concentration, which in turn, is determined
by the status of the Av|/. JG-1 forms monomers at low dye concentrations, and aggregates
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at higher concentrations. The A\j/ of normal, healthy mitochondria is polarized and JC-1
is rapidly taken up hy such mitochondria. This uptake increases the concentration
gradient of JC-1 leading to the formation of JC-1 aggregates (known as J-aggregates)
within the mitochondria. JC-1 aggregates show a red spectral shift resulting in higher
levels of red fluorescence emission that is measured in the Red (FL-2) channel on most
flow cjdometers. JC-1 does not accumulate in mitochondria with depolarized Av|/ due to
apoptosis and remains in the cjdoplasm as monomers. JC-1 that fluoresces in the FL-1 is
indicative of depolarized A\\i. The JC-1 assay will measure the red/green fluorescence in
a quantitative approach using the fluorescence-activated cell sorter (FACS). MCF-7 cells
will be cultured to an optimal density of 1.0x10^ in 25T flasks and treated with RSV (10
M). Cells will be detached and centrifuged at 800 g for 5 minutes at room temperature.
Freshly prepared JC-1 Working Solution (0.5 ml) was added to each pellet, followed by
incubation 15 min at 37°C in a CO2 incubator. Cells will be resusupended in Ix Assay
Buffer and analyzed immediately by flow c5d:ometry using the Cellquest program (Becton
Dickinson).
Statistical analysis
Values are expressed as the mean ± SEM. Statistical differences between mean
values were determined by one-way ANOVA, SPSS 11.0 software (SPSS, INC.,




Resveratrol effect on cell growth and survival
To assess cell proliferation, MCF-7 cells were treated with RSV and examined by
BrdU incorporation. Fig. 2A shows that BrdU incorporation by MCF-7 cells treated with
10"^ M RSV was significant when compared with control (p<0.01) and RSV 10"^
(p<0.05) treated groups at 24 and 48 hrs. Since IGF-II exerts its effects by binding mainly
to the IGF-IR, we blocked the IGF-IR on cells treated with 10"® M RSV. Our results show
that IGF-IR antibody significantly decreased BrdU incorporation in MCF-7 cells treated
with RSV 10"® M (p<0.05).
Increasing concentrations of proIGF-II (10-100 ng/ml) were added to MCF-7 cells
treated with RSV (10"^ M) to determine if proIGF-II could prevent cell death. Figure 2B
shows that addition of pro-IGF-II at 24 and 48 hrs, significantly prevented cell death even
at the lowest IGF-II concentration used (10 ng/ml). The IGF-II response plateau at 50
ng/ml. This data indicates that proIGF-II is able to rescue MCF-7 cells (p < 0.01) from
the growth inhibitory effect of RSV (10"^ M).
The MTT cell viability assay was used to determine if RSV effect on IGF-II
modulates cell survival of MCF-7, T47D (ER+) breast cancer cells, Hs578T (ER- breast
cancer cell line) and MCF-lOA (ER-) breast epithelial cells. Figure 3A shows that
treatment of MCF-7 cells with RSV (10"'^M) caused a significant decrease in cell
viability at 24 and 48 hrs. In contrast, treatment with RSV (10"® M) increases cell
survival, but this increase is statistically significant at 48 hrs (lower panel A). Addition of
the IGF-IR antibody blocks the effect of RSV (10"®) at 24 and 48 hrs (fig. 3 A).
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To determine whether the observed effects of RSV on IGF-II are mediated
through the estrogen receptor (ER), MCF-7 cells treated with RSV (10 ̂ and 10
M) were co-incubated with or without the estrogen antagonist tamoxifen (TAM). TAM
(10'^ M) completely abolished the increase in cell number induced by RSV (10'^ M) (fig.
3B), 24 and 48 hrs post treatment (p<0.001). No significant difference was observed
between the group treated with RSV (10'"^ M) and the group treated with TAM and RSV
(10"') (fig. 3B).
We also assessed the effect of RSV on IGF-II protein levels and cell growth in the
estrogen receptor positive (ER+) T47D, estrogen receptor negative (ER-) Hs578t and
MCF-IO cells. Figure 4A similar effect on cell growth, as seen on MCF-7 cells, was
observed on T47D cells, were RSV (10"^ M) induced increase in cell number (*p<0.05),
while the opposite effect was seen with RSV (10""^ M) (**p<0.01).
Figure 5 shows that RSV 10"^ M had no effect on the MCF-10 (panel A) and Hs578t
(panel B) cell lines, 24 and 48 hrs post-treatment. Although HS578t and MCF-10 cells do
not express ERa, treatment with RSV (10"^ M) caused cell growth inhibition of both cell
lines, as assessed by the MTT assay. Addition of proIGF-II (10-100 ng/ml) to RSV (10
M) treated MCF-IO cells, blocked RSV growth inhibitory effect (Fig. 10).
Effect of resveratrol on IGF-II protein secretion
Next, I screened the effect of different RSV concentrations (10'^ -10""^ M) on IGF-
II protein secretion in MCF-7 cells. As seen in figure 6 the only changes in IGF-II protein
were detected with RSV treatment of 10""^ and 10"® M, thus we expanded our experiments
using only RSV 10""^ and 10"® M for further characterization. Figure 7A shows a Western
blot of IGF-II secreted at 24 and 48 hr after RSV treatment at 10""^ and 10"® M. Our results
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show a differential effect on IGF-II secretion that is RSV concentration dependent.
Treatment with 10'^ M RSV induced a two-fold increase in proIGF-II secretion (17kDa)
while higher RSV concentration (lO""^ M) induced 30% decrease in IGF-II secretion.
Figure 8 shows that RSV (lO '^M) inhibits IGF-II and RSV (10 ̂ M) stimulates IGF-II in
T47D breast cancer cells at 24 and 48 hrs. Figure 7A (lower panel) show bar graph
representations of densitometric analysis of IGF-II densitometry units (integrated density
units, IDV) normalized to P-actin protein units on three separate experiments. As seen,
treatment with RSV (lO'^^M) significantly (*p<0.05) inhibited IGF-II, while RSV (10 ®
M) significantly increased IGF-II protein levels (**p<0.01). Please note that although
only one western blot is depicted as a representative experiment, the bar graphs represent
3 separate experiments done in triplicate (3 western blots per experiment).
Since estradiol regulates both, IGF-I and IGF-II mRNA (both genes have the ER
consensus sequence), we measured IGF-I protein secretion into the media of MCF-7 cells
to determine if RSV also regulated IGF-I. No IGF-I (proIGF-I or mature) was detected in
media from control or RSV treated cells at any studied concentration (Fig.7B). Thus,
even though IGF-I and IGF-II are regulated by estradiol, RSV regulates only IGF-II.
Modulation ofIGF-II mRNA by resveratrol
The concentration-dependent effect of RSV on IGF-II gene expression was
assessed by Northern blot analysis following 12 (fig. 9A) and 24 (fig 9B) hrs treatment.
Since IGF-II protein levels changed at 24 and 48 hrs, we reasoned that mRNA changes
may occur earlier and chose to analyze mRNA levels at 12 and 24 hrs post-treatment.
Figure 9 (A, B) shows increased IGF-II mRNA, when cells were treated with 10"^ M
RSV. In contrast, a decrease in IGF-II mRNA was observed when cells were treated with
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lO'"^ M RSV. Figure 9 (lower panels A and B) show bar graph of densitometric analysis
of IGF-II densitometry units (integrated density units, IDV) normalized to Cyclophilin
mRNA densitometry units on three separate experiments. Please note that only one
northern blot is shown for representation purposes, while data from 3 separate
membranes of 3 different experiments was used in the bar graphs below for the statistical
analysis. The increase in IGF-II mRNA when cells were treated with RSV (10"^ M) and
compared to control was 3 fold at 12 hrs (p<0.01) and 2.5 fold at 24 hrs (p<0.01). In
contrast, IGF-II mRNA decreased 3 fold (p<0.05) at 12 hrs and 2 fold (p<0.05) at 24 hrs
when cells were treated with 10'"^ M RSV. The most significant differences (p<0.001)
were seen between the IGF-II mRNA of cells treated with RSV 10"^ as compared to cells
treated with RSV lO"'^; six fold difference at 12 hrs and 4.5 fold at 24 hrs.
No changes in IGF-II expression were observed in the ER- MCF-10 (figure 10)
and Hs578t (figure 16) cell lines after RSV treatment (10'^ M or 10'"^ M)
RSV effect on Cathepsin D secretion
We also examined CD secretion by MCF-7 cells treated with varying
concentrations of RSV (10"^-10"'* M). Our results indicate that RSV exerts a concentration
dependent effect on CD secretion 24 and 48 hrs post-treatment, as shown in Fig; 12A.
RSV (10"^) increases while RSV (IC*) decreases CD secretion. Thus, we concentrated
our study on RSV treatment at 10"^ and 10"^ M. Figure 12B (upper panel) shows
representative Western blots (of 3 independent experiments). As seen on this figure, RSV
(10"^ M) increased CD secretion (p<0.01) while RSV (10"^ M) inhibited CD secretion
(p<0.01). Please note that only one western blot is shovm for representation purpose only.
Figure 12 (lower panel B) shows a bar graph representation of densitometric analysis of
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CD densitometry units (integrated density units, IDV) normalized to P-actin densitometry
units of three separate experiments. As seen, RSV induced significant (p< 0.01) changes
in CD secretion when cells were treated at 10'^ and 10"^ M. CD changes correlated with
IGF-II levels as observed in figure 12C.
Similarly, figure 13A (upper panels) shows RSV effect on CD secretion in T47D
breast cancer cell after 24 and 48 hrs of treatment. RSV (10'^ M) induced an increase in
CD secretion (p<0.01) while RSV (10"'* M) inhibited CD secretion (p<0.01). Figure 13A
(lower panels) show bar graph representation of densitometric analysis of CD normalized
to P-actin densitometry units of three separate experiments. Likewise, as seen in MCF-7
cells treated with RSV CD changes correlated with IGF-II levels (figure 13B).
RSV ejfect on Cathepsin D mRNA levels
The effect of RSV on CD gene expression in MCF-7 cells was assessed by
Northern blot analysis. Figure 14A shows a representative northern blot (of 3 separate
experiments) of CD at 12 and 24 hrs after RSV treatment. Since CD protein levels
changed at 24 and 48 hrs, we reasoned that mRNA changes may occur earlier and chose
to analyze mRNA levels at 12 and 24 hrs post-treatment. The decrease observed in CD
mRNA when cells were treated with RSV (10"'* M) is significant at 12 (p<0.05) and 24
hrs (p<0.01). In contrast, there were no changes in CD mRNA when cells were treated
with RSV (10"^ M). Figure 14A (lower panel) shows bar graph representations of
densitometric analysis of CD densitometry units (integrated density units, IDV)
normalized to eyelophilin mRNA densitometry units on three separate experiments.
Please note that only one northern blot is shown for representation purposes, while data
from 3 separate membranes of 3 different experiments were used in the bar graph below
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for the statistical analysis. Figure 14B shows that RSV treatment at high concentration
(10"%) inhibited IGF-II mRNA at 12 and 24 hrs, while RSV (10"^ M) increased IGF-II
mRNA. Furthermore, since the increase in CD secretion seen when cells are treated with
RSV (10"^ M) does not correlate with increased CD mRNA levels, we conclude that
treatment with RSV (10"^ M) modulated CD secretion by increasing the levels of IGF-II.
Transfection withproIGF-IIsense cDNA induces increased CD secretion in Hs578t and
MCF-lOA cells
We also addressed the question of whether IGF-II modulates CD routing and
secretion on hormone-independent ERa(-) breast cancer (Hs578t) and epithelial (MCF-
lOA) cells. We transfected Hs578t and MCF-lOA cells with proIGF-II sense cDNA and
measured CD protein secretion and mRNA levels after 48 hrs. Figure 15A shows IGF-II
and CD Western blots from IGF-II transfected cells (Clones IIB8, IIB9 and IIBl 1) or
vector only (CMV) transfected Hs578t cells compared to non-transfected cells. As clearly
seen, all transfected clones secreted high amounts of pro-IGF-II that correlated with
increased CD secretion (15 A). IGF-II was undetectable in control cells, although reactive
CD bands were observed. Figure 14B shows corresponding Northern blots. Although
three different IGF-II transcripts are seen (4.8, 2.2, and 0.7 kb), the major form
transcribed by Hs578t cells corresponds to the 2.2 kb transcript. No significant change in
CD mRNA is seen. Cyclophilin was used as a loading control. Similarly, figures 15C and
D show MCF-lOA cells Western and Northern blot analyses of proIGF-II and CD from
transfected (clones IIC5, IID5 and IIF4) and control cells (CMV). As observed in figure
15D, all IGF-II transcripts (4.8, 2.2, and 0.7) increase in transfected MCF-lOA cells. The
2.2 kb transcript represents mRNA from promoter 2 and the 0.7 kb is the transfected IGF-
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II cDNA. Interestingly, CD mRNA also increased significantly in transfected MCF-lOA
cells when compared to control cells. Cyclophilin was used as a loading control.
Resveratrol effect on IGF-II and CD secretion in ER(-) human breast cancer and
epithelial cells
Since RSV exerts both ER-dependent and ER-independent effects on human
breast cell lines and RSV (10'"^) regulated CD gene expression in ER (+) breast cancer
cells, we also studied IGF-II and CD secretion in Hs578t breast cancer and MCF-lOA
breast epithelial cell lines after RSV treatment (10'^ and 10""^ M). For this purpose, we
measured IGF-II and CD protein secretion in RSV treated ERa(-) Hs578t breast cancer
and MCF-lOA breast epithelial cells. Figure 16 (right panel) shows a representative
Western blot (of 3 separate experiments) of IGF-II and CD secreted from Hs578t cells, at
24 and 48 hrs. As seen, control or RSV treated Hs578t cells did not secrete IGF-II
(mIGF-II/proIGF-II) and no changes in CD secretion were observed after RSV treatment.
Figure 16 (left panel) shows that MCF-lOA cells secrete IGF-II, but RSV treatment does
not change IGF-II or CD secretion from MCF-lOA cells after 24 and 48 hrs.
Effect ofRSV and IGF-II on Bcl-2 and survivin protein levels
We also studied the effect of RSV (lO""^ M) on Bcl-2 and survivin protein levels. As
seen on figure 17 (upper panel), RSV (10"^) induced a significant decrease (p<0.05) in
Bcl-2 protein levels 3 hrs post-treatment. Co-treatment with the mature or the precursor
form of IGF-II (100 ng/ml) blocked RSV (lO'"^) inhibitory effect. Furthermore, as seen on
figure 17, addition of proIGF-II (but not mIGF-II) to RSV (10"'*) treated cells induced a
significant increase (p<0.05) in Bcl-2 protein levels as compared to control group 6 hrs
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post-treatment. Figure 18 shows a significant decrease (p<0.05) in survivin levels after
RSV (10""^) treatment. Addition of IGF-II (mIGF-II or proIGF-II) did not block RSV
inhibitory effect on survivin levels 3 hrs post-treatment. Noteworthy, addition of proIGF-
II, but not mIGF-II, induced an increase in survivin levels 6 hrs post-treatment as
compared to RSV (10'"^) treated group. Figures 17-18(lower panels) show bar graph
representations of densitometric analysis of Bcl-2 and survivin densitometry units
(Integrated Density Units, IDV) normalized to P-actin densitometry units on 3 separate
experiments. Please note that although only one western blot is depicted as a
representative experiment, the bar graph represents three separate experiments done in
triplicate (three western blots per experiment).
Effect ofRSV onBcl-2 and survivin protein levels in proIGF-II transfected MCF-7 cells
To further confirm the stimulatory effect of proIGF-II on Bcl-2 and survivin, we
transfected MCF-7 cells with proIGF-II sense cDNA and measured Bcl-2 and survivin
protein levels by Western blot, 3 and 6 hrs after RSV (10"'^ M) treatment. As seen on
figure 19 transfection with IGF-II sense cDNA blocked RSV (10""^ M) inhibitory effect on
Bcl-2 (panel A) and survivin (panel B) as early as 3 hrs post-treatment.
RSV and IGF-II effects on Bcl-2 and survivin mRNA levels
RSV (10""^ M) and IGF-II effects on Bcl-2 and survivin gene expression were
assessed by Real Time-PCR following 6 hrs co-treatment. To evaluate the effect of
mature and precursor IGF-II (mIGF-II and proIGF-II) on Bcl-2 and survivin gene
expression in RSV (10""^ M) treated cells, MCF-7 cells were also incubated in the
presence of 100 ng/ml of either mIGF-II or proIGF-II. As seen on figure 20, addition of
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proIGF-II to RSV treated cells induced a two fold increase in survivin mRNA levels, but
not in Bcl-2 mRNA. On the contrary, mlGF-II did not induce any significant changes in
survivin gene expression, although a decrease in Bcl-2 levels is seen.
Effect ofRSV and IGF-II (mIGF-II and proIGF-II) on Caspase - 7 activation
Caspase 7 enzymatic activity was measured by a caspase activation assay. Figure
21 shows an increase in relative fluorescence units (RFU) induced by proteoljdically
released fluorochrome from the DEVD-AMC substrate, 3 (panel A) and 6 (panel B) hrs
after RSV (10""^) treatment. On the contrary, a decrease in caspase activation was
observed when cells were co-treated with IGF-II (100 ng/ml). Of note, proIGF-II induced
a statistically significant decrease (p<0.01) in caspase activity, while mIGF-II did not
(p>0.05).
RSV and IGF-II effects on mitochondrial membrane potential
In order to elucidate RSV (lO'"^) and IGF-II effects on mitochondrial membrane
depolarization as an indicator of apoptosis, the JC-1 assay was performed. The JC-1 dye
does not accumulate in mitochondria with depolarized Av|/ due to apoptosis and remains
in the cytoplasm as monomers. These monomers have lowered fluorescence in the FL-2
channel. As seen in figure 22, a significant increase in FL-1 channel fluorescence occurs
with RSV (10""^) treatment 9 hrs post-treatment when compared to control and proIGF-II
treated cells. Of note, mIGF-II was not able to protect the cells as significantly as
proIGF-II, as shown by a greater increase in the FL-1 channel fluorescence indicative of
mitochondrial membrane depolarization.
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RSVeffect on cell survival ofIGF-II transfected MCF-7 cells
To assess cell survival, IGF-II (mIGF-II or proIGF-II) transfected MCF-7 cells
were treated with RSV (10"'' M) and examined by the MTT assay after 3 and 6 hrs of
treatment. Figure 23 shows a significant decrease in cell number in RSV treated cells
when compared to control after 3 (p<0.01) and 6 (p<0.001) hrs treatment. A significant
increase in cell survival (p<0.01) was seen in MCF-7 cells transfected with proIGF-II
than in cells transfected with mIGF-II (p<0.05) after 6 hrs treatment when compared to
control. Noteworthy, RSV treatment induced a more significant decrease in MCF-7
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RSV/IGF-II treatment (48 hrs)
Figure 2. BrdU incorporation in MCF-7 breast cancer cells (ER+) treated with RSV and
co-incubated with an IGF-I receptor-blocking antibody (panel A). Data are presented as
the mean ± standard error of three independent experiments. Asterisks indicate values
significantly different from control (*p<0.05), or significantly different from 10"® M RSV
treatment (**p<0.05). Panel B shows BrdU incorporation data from MCF-7 cells treated
with RSV and co-incubated with various concentrations of recombinant human proIGF-II
(10-100 ng/ml). Data are presented as the mean ± standard error of three independent




Control Antl-IGF-IR 10-4 10-6 10-6/Anti-IGF-IR
RSV treatment (24 hrs)
■3 20000
O
Control Anti-IGF-IR 10-4 10-6 10-6/Anti-IGF-IR




















10-6 10-6 10-4 10-4
+  - +
RSV/TAM treatment (24 hrs)
I i«
10-6 10-6 10-4 10-4
+  - + - +
RSV/TAM treatment (48 hrs)
Figure 3. MTT assay of MCF-7 cells treated with RSV and co-incubated with an IGF-I
receptor-blocking antibody (panel A). Data are presented as the mean ± standard error of
three independent experiments. Asterisks indicate values significantly different from
eontrols (*p<0.05), or 10"® M RSV (**p<0.05). Panel B shows MTT assay results from





























RSV treatment (48 hrs) T47D cells
Figure 4. T47D breast cancer cells (ER+) growth study (MIX assay), after 24 and 48 hrs
treatment with RSV (10"^ and 10""^ M). Data are presented as the mean ± standard error of
three independent experiments. Asterisks indicate values significantly different from
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Figure 5. MCF-10 breast epithelial cells (panel A) and Hs578t (ER-) breast cancer cells
(panel B) growth study (MTT assay), after 24 and 48 hrs treatment with RSV (10"^ and
10""^ M). Data are presented as the mean ± standard error of three independent
experiments. Asterisks indicate values significantly different from controls (*p<0.05).
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Figure 6. Western blot of IGF-II secreted from MCF-7 cells treated with various
concentrations of RSV 24 and 48 hrs post-treatment. The 17 kDa band represents
proIGF-II and is the only IGF-II form secreted by MCF-7 cells. P-aetin was used as
protein loading control (42kDa). Immunoreactive bands for IGF-II or P-actin were












































Figure 7. Panel A shows a Western blot of proIGF-II secretion at 24 and 48 hrs after
RSV treatment. The 17 kDa band represents proIGF-II and is the only IGF-II form
secreted by MCF-7 cells. P-actin was used as protein loading control (42kDa).
Immunoreactive bands for IGF-II or p-actin were identified using ECL, scanned by
densitometry and normalized to P-actin. Lower panel A shows a bar graph of IGF-II data
normalized to p-actin and presented as the mean ± standard error of three separate
experiments. Asterisks indicate values significantly different from controls (*p<0.05,
**p<0.01). Panel B shows an IGF-I Western blot where no IGF-I is detected.














































RSV treatment (24 hrs) T47D cells
10-6 10-4
RSV treatment (48 hrs) T47D cells
Figure 8. Western blot of IGF-II seereted from T47D cells treated with RSV (10 and
10""^ M). A representative Western blot of proIGF-II secretion at 24 and 48 hrs after RSV
treatment is shown. P-actin was used as protein loading control (42kDa). Immunoreactive
bands for IGF-II normalized to P-actin. Panel A shows a graph bar of IGF-II data
















































Figure 9. Northern blot of IGF-II mRNA from MCF-7 cells treated with RSV (10'^ 10"'*
M). Total RNA was isolated from control cells and cells treated with RSV 10'^ or 10"'^ M
for 12 (panel A) or 24 hrs (panel B). The 4.8 kb band represents the IGF-II mRNA
transcript generated from promoter 3 (P3). Cyclophilin was used as a loading control. A
representative Northern blot is shown for each treatment time (panels A and B). Bar
graph data (lower panels A and B) represents IGF-II mRNA data normalized to
cyclophilin and presented as the mean ± standard error of three independent experiments.
Asterisks indicate values significantly different from controls (*p<0.05, **p<0.01).
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Figure 10. Western and northern blot analysis of IGF-II secreted from MCF-10 cells.
Panel A shows a representative Western blot of proIGF-II secretion at 24 and 48 hrs of
RSV treatment, p-actin was used as protein loading control. Panel B shows northern blot
of IGF-II mRNA at 12 and 24 hrs of RSV treatment. Cyclophilin was used as a loading
control. Immunoreactive bands for IGF-II were normalized to P-actin or cyclophilin.
Lower panels (A and B) show graph bar of IGF-II data normalized to p-actin or






























RSV treatment (48 hrs) MCF-10 cells
Figure 11. BrdU incorporation data from MCF-10 cells treated with RSV and co-
incubated with various concentrations of recomhinant human proIGF-II (10, 50 and 100
ng/ml). Data are presented as the mean ± standard error of three independent
experiments. Asterisks indicate values significantly different from controls (*p<0.05), or
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Figure 12. RSV concentration-dependent effect on CD secretion by MCF-7 eells after 24
and 48 hrs treatment. Panel A shows a Western blot (WB) of CD secreted by MCF-7
eells, treated with different RSV eoneentrations (10"^-10"'^). Panel B shows a
representative WB of CD secreted by cells treated with RSV (10"®M) or (IC'^M) dose of 3
separate experiments (upper panel). Lower panel B shows bar graph representations of
CD data normalized to P-aetin and presented as the mean ± standard error of three
separate experiments. Asterisks indieate values significantly different from eontrols
(*p<0.05, **p<0.01). Panel C shows WB analysis of IGF-II at 24 and 48 hrs of RSV
treatment (10'^ and lO'^^M).
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Figure 13. RSV concentration-dependent effect on CD secretion by T47D eells after 24
and 48 hrs treatment. Panel A shows a representative WB of CD secreted by cells treated
with RSV (10"®M) or (IC'^M) dose of 3 separate experiments (upper panel). Figure 2A
(lower panel) shows bar graph representations of CD data normalized to p-actin and
presented as the mean ± standard error of three separate experiments. Asterisks indicate
values significantly different from controls (**p<0.01). Panel B shows WB analysis of
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Figure 14. RSV concentration-dependent effect on CD mRNA levels in MCF-7 eells (12
and 24 hrs). Upper panel A shows a representative CD Northern blot (NB) from RSV
treated (10"® and 10"^M) MCF-7 cells after 12 and 24 hrs treatment. The 2.2 kbband
represents cathepsin D mRNA. Lower panel A shows bar graph representations of CD
mRNA data normalized to Cyclophilin and presented as the mean ± standard error of
three separate experiments. Asterisks indicate values significantly different from controls
(*p<0.05). Panel C shows Northern blot analysis of IGF-II mRNA (the 4.8 kb band
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Figure 15. IGF-II and CD WB and NB analyses from Hs578t and MCF-lOA cells 48 hrs
after fransfeetion with proIGF-II sense cDNA. Panel A shows WB of IGF-II (10 and 17
kDa immunoreactive bands) and CD (52 and 50 kDa bands) secreted by Hs578t cells
transfeeted with proIGF-II sense cDNA. Panel B shows NB of IGF-II (4.8, 2.2 and 0.7 kb
mRNA) and CD (2.2 kb mRNA) from transfeeted Hs578t cells. Cyclophilin was used as
a loading control. Similarly, panels C and D show WB and NB respectively, of IGF-II


































Figure 16. IGF-II and CD WB from RSV treated (10"^ and lO""* M) Hs578t and MCF-
lOA cells. Panel A shows a representative WB of IGF-II (17 kDa) and CD (52, 50, 30
kDa) secreted by Hs578t cells after 24 and 48 hrs of RSV treatment respectively The 7.5
kDa band represents recombinant human IGF-II used as a positive control. Similarly,
Figure 5B (upper panel) shows a representative WB of IGF-II and CD secreted by MCF-
lOA cells after 24 hrs of RSV treatment, while lower panel B shows IGF-II and CD WB









































RSV I IGF-II treatment (6 hrs)
prolGF-ll
Figure 17. Bcl-2 Western blot analysis 3 and 6 hrs after RSV and IGF-II (mature and
precursor forms) treatment. Upper panel shows Bcl-2 Western blot (26 kDa) produced by
MCF-7 cells 3 and 6 hrs after RSV (IC*) and mIGF-II or proIGF-II (100 ng/ml)
treatment. Corresponding densitometric analyses of Bcl-2 densitometry units (IDV)
















































RSV I IGF-II treatment (6 hrs)
+
prolGF-l
Figure 18. Survivin Western blot analysis 3 and 6 hrs after RSV and IGF-II (mature and
precursor forms) (100 ng/ml) treatment. Lower panels show bar graph of survivin data
normalized to P-actin an presented as the mean =1= SE of three separate experiments.
Asterisks indicate values significantly different from controls (*p<0.055 **p<0.01).
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Figure 19. Bel-2 and survivin Western blot analysis of RSV (10""^ M) treated proIGF-II
transfected MCF-7 cells. Panel A shows representative Western blots of Bcl-2 at 3 and 6
hrs after RSV treatment. Similarly panel B shows representative Western blots of
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Figure 20. RSV (R) effect on Bcl-2 and survivin gene expression in MCF-7 cells co-
treated with mIGF-II (S I) or proIGF-II (L-I)and assessed by Real-Time PGR. Changes in
Bcl-2 and survivin mRNA levels are expressed as fold increase relative to control cells.













































Caspase 7 activation assay (6 hrs)
prolGF-
Figure 21. RSV effect on caspase -7 activation. Panels A and B show caspase 7
activation assay data represented as relative fluorescence units (RFU), 3 and 6 hrs after
RSV and mature or precursor IGF-II (100 ng/ml) treatment. Asterisks indicate values
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Kev Name Parameter Gate
CONTROL-FL1.001 FL1-H No Gate
-4RESV-FL1.002 FL1-H No Gate
-4RESV+SIGFII-FL1.003 FL1-H No Gate
-4RESV+LIGFII-FL1.004 FL1-H No Gate
Figure 22. RSV effect on mitochondrial membrane depolarization as an indicator of
apoptotic cell death using the potential-dependent lipophilic cation JC-1. The JC-1 assay
measured the red/green fluorescence in a quantitative approach using the fluorescence-
activated cell sorter (FACS). The FL-1 channel associates with membrane depolarization































mIGF-ll mIGF-ll prolGF-ll prolGF-ll
RSV treatment (24 hrs)
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Figure 23. MTT assay of MCF-7 cells transfected with mature IGF-II or proIGF-II 24
and 48 hrs after RSV (10'"^) treatment. Data are presented as the mean ± SE of three






Cancer is a major public health problem in the United States and other developed
countries. Breast cancer represents the most common cancer among women in the US.
212,930 new cases have been estimated for 2005. California has the highest number of
cases per state (21,170). Although the carcinogenic process may be driven by mutation,
there are clearly many epigenetic variables, particularly those relating to the action of
autocrine, paracrine and endocrine regulatory molecules, which include the IGFs, that
constitute important determinants during the latent period before invasion and metastasis
occur. Pharmacologic modulation of these regulatory pathways, through the effective use
of drugs and nutrients, offers great potential for the treatment of cancer (Spom and Suh,
2000).
Resveratrol-induces IGF-II expression in ER+ Breast Cancer Cells
Resveratrol (RSY) is a promising and novel diet-derived cancer chemotherapeutic
agent. RSY is a phytoalexin generated in response to environmental stress or pathogenic
attack in grapes, mulberries, peanuts and plants of the Cassia quinquangulata family
(Goldberg et al, 1996). RSY, a relatively new member of a class of chemopreventive
agents like retinoids and other diet-derived compounds, has been shown to retard or
1
prevent steps of carcinogenesis and mediate differential responses in various tissues,
organs and in vitro models. RSY inhibits the growth of cancer cells of different origins
(Sciacca et al 1999, 2000; Denley et al 2004; Scott and Firth 2004). However, the effect
of RSY on breast cancer cell growth and ER-mediated gene activation is a controversial
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subject under intense investigation. Several studies reported that treatment with RSV
stimulated cell proliferation of the ER-positive, T47D and MCF-7 breast cancer cell lines,
(Gehm et al 1997; Nakagawa et a/2001). In contrast, other reports have shown that RSV
treatment inhibited cell growth of both ER-positive and ER-negative breast cancer cells
(Lu and Serrero 1999; Hsieh et al 1999; Damianaki et al 2000; Mgbonyebi et al 1998).
Molecules involved in RSV biphasic response, and risks associated with RSV
usage remain mostly unknown. Our study demonstrated that RSV regulates IGF-II gene
expression in a dose-dependent manner in MCF-7 and T47D breast cancer cell lines. At
low concentrations (10'® M), RSV stimulated IGF-II gene expression leading to an
increase in proIGF-II secretion. Furthermore, the increase in proIGF-II levels correlated
with an increase in MCF-7 and T47D cell growth, suggesting that IGF-II mediated RSV
stimulatory effects, potentially increasing the risk of breast cancer growth.
Our previous studies have shown that both MCF-7 and T47D cells are very
sensitive to IGF-II, they express IGF-I receptors and that IGF-II actions are mediated
through the IGF-I receptor (DeLeon et al 1988, 1992). Since the IGF-IR antibody
blocked the stimulatory effect of RSV treatment (10'® M) in this study, we conclude that
the IGF-II effect is mediated, primarily, through the IGF-IR. In addition, the blocking
effect of the antibody on both, the MTT (used to estimate cell number and viability) and
the BrdU assays (DNA sjmthesis) also demonstrated that IGF-II regulates both cell
survival and growth.
Even though our study demonstrated that RSV does not regulate IGF-II in the ER
negative MCF-lOA breast epithelial cell line, exogenously added pro-IGF-II was able to
rescue these cells as well as the ER(-i-) breast cancer cells from RSV (10''* M) induced
growth inhibition and cell death. These results demonstrate that all cell lines studied are
86
responsive to IGF-II, but only ER+ cells are stimulated by RSV (10'^ M). Thus, RSV
stimulatory effect requires the ER while the inhibitory effect of RSV is ER independent.
RSV inhibits the binding of E2 to the ER and induces ER-dependent
transcriptional activation of genes with an estrogen-response element (ERE). This effect
can be inhibited by specific estrogen antagonists (Gehm et al 1997). TAM, an estrogen
antagonist, suppresses transcriptional activity by blocking E2 co-activator binding and
promoting co-repressor recruitment (Yamamoto et al 2001). Our data demonstrated that
TAM inhibits RSV (10"^) induced cell growth, thus confirming that the ER is required in
mediating RSV stimulatory effect on IGF-II levels.
Of note, RSV did not stimulate IGF-I. Both, IGF-I and IGF-II are regulated by E2
because both genes have the ERE (Yee and Lee, 2000). Since our study showed that RSV
regulated IGF-II, not IGF-I, RSV regulation of IGF-II is might be distinct from E2
regulation of these peptides.
Many reports from other laboratories have shown a biphasic effect of estrogen or
RSV on many different systems, as we have observed with RSV in our study. Amara and
Dannies (1983) reported that estradiol stimulated GH cell growth at low concentration but
significantly inhibited growth at higher concentrations. Likewise, Kuwajerwala et al
(Kuwajerwala et al, 2002) demonstrated that RSV exerted opposing effects on cell cycle
progression in prostate cancer cells. RSV induced the cell cycle S phase at low
concentrations but it inhibited DNA synthesis at high concentrations.
The specific signaling pathways activated by RSV are largely unknown. Since
this estrogen antagonist binds the ER it will induce genomic effects through the ER
pathway as seen with proIGF-II regulation in our study. Other reports have also shown
that RSV can stimulate non-genomic effects by binding to the estrogen membrane
87
receptor (Pozo-Guisado et al, 2004). The changes in IGF-II induced by RSV in ER(+)
cells will affect gene targets in the IGF-I receptor pathway as well as genes in the insulin
receptor (isoform A) pathway. To our knowledge, there is no published data showing
RSV stimulation of IGF-II or its downstream targets.
Our study shows that RSV effects on cell growth are mediated by proIGF-II.
Furthermore, proIGF-II effects are mediated through the IGF-IR. In addition, since RSV
regulates proIGF-II in ER(+) (not ER-) breast cancer cells and this effect is blocked by
TAM, we conclude that RSV regulation of IGF-II is mediated through the ER. In
contrast, the inhibitory effect of RSV is independent of the ER presence since RSV (10
M) inhibited proliferation and cell survival of ER(-) cells.
IGF-II overexpression leads to Cathepsin D secretion in Breast Cancer Cells
The lysosomal enzyme eathepsin-D (CD) and insulin-like growth faetor-II (IGF-
II), which shares a common IGF-II/mannose-6-phosphate (M6P) transmembrane
receptor, are both synthesized and secreted by breast cancer cells, upon which they might
exert an intracrine/autocrine control on proliferation.
Cathepsin D (CD) is a prognostic indicator of metastasis and survival for breast
cancer patients (Rochefort et al, 2000), making this protease an important target for
chemotherapeutic agents. Because both proteins, IGF-II and CD bind to the IGF-
II/M6PR, binding of one ligand interferes with the binding of the other ligand (Faridi et
al, 2004).
Treatment with RSV (10"^ M) caused an increase in CD secretion in MCF-7 and
T47D cells without a corresponding increase in CD mRNA. Increased IGF-II secretion
was associated with an increase in IGF-II mRNA levels. Although CD is regulated by E2,
our results indicate that RSV-induced increase in CD secretion does not correlate with
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CD mRNA changes. In the eontext of CD gene aetivation, it is known that ERa
interaction with USF-1 and USF-2 in the CD promoter is a critical step in hormone
aetivation of CD gene transcription, a step that might not take place when RSV (lO^M)
binds the ERa.
Thus, changes in CD secretion are related to the derouting of intraeellular CD
caused by IGF-II expression. Since normal mammary cells do not express IGF-II, no
secretion of CD should oecur. Nevertheless, MCF-lOA eells express the 4.8 and 2.2 IGF-
II mRNAs. Increased IGF-II expression in these "normal" mammary eells further
increases secretion and higher expression of CD mRNA levels. This finding is of great
significance, beeause in addition to indueing degradation of the extracellular matrix
(ECM), CD also eauses proteolysis of IGF binding proteins (IGFBPs) leading to
increased IGF bioavailability and stimulated cell growth (Conover and DeLeon, 1993;
Clausen et al, 1997). Secreted pCD is involved in eancer eell growth and/or
differentiation. Since MCF-lOA cells were derived from tissue with fibrocystie changes,
we propose that they represent the earlier steps in the development of breast cancer. By
promoting CD secretion IGF-II expression alters the cell mieroenvironment increasing
cell proliferation. Thus, both IGF-II and CD may be associated with the increased risk of
breast cancer observed in women with fibrocystie disease. On the contrary, treatment
with RSV (10"^ M) had an inhibitory effeet on CD gene expression and protein secretion
in ER(+) MCF-7 and T47D cells.
RSV has also been shown to exert ER-independent effects on both, cells
expressing the ER and cells that do not express the ER-a. Reeently, RSV has been shown
to activate adenylyl cyelase (AC) /kinase-A pathway in ER(+) MCF-7 as well as in ER(-)
MDA-MB-231 breast eancer eell lines (El-Mowafy and Alkhalaf, 2003). This data
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indicates that recruitment of AC by RSV is not confined to ER(+)MCF-7 cells, thus RSV
effect on AC is independent of the cell ER status. Our study also showed that RSV effect
on CD secretion is only present in ERa (+) human breast caneer cells and not in ERa (-)
cells. Of note, the 52 and 30 kDa CD forms were present in the conditioned media from
MCF-lOA cells, suggesting that a sufficiently acidie pH, whieh is required for CD
processing and activation and is normally found in the microenvironment of malignant
cells, might also be found in the MCF-lOA microenvironment, a significant finding in
terms of potential malignant transformation.
CD is not only associated with cancer progression, but appears to he a rate
limiting faetor in stimulating in vitro and in vivo tumor growth; CD stimulates directly or
indirectly both, cancer cell proliferation and tumor angiogenesis independently of its
proteolytie aetivity and may provide some protection against tumor apoptosis (Berchem
et al, 2002).
IGF-II Regulates Genes Involved in the Apoptotic Pathway
RSV has been shown to inhibit cell survival and induee apoptosis of cancer cells
of different origin by mechanisms including: a caspase-independent pathway with
downregulation of NF-kappaB (Pozo-Guisado et al, 2005), serine phosphorylation and
acetylation of p53 tumor suppressor protein (Zhang et al, 2004), sensitization for TRAIL-
induced apoptosis (Fulda and Debatin, 2004), or through activation of CD95 signaling-
dependent apoptosis (Clement et al, 1998).
Bcl-2 and survivin represent important proteins involved in the control of the
mitoehondrial apoptotie process. Bcl-2 and several pro-survival proteins associate with
the mitoehondrial outer membrane and the endoplasmic retieulum/nuclear membrane and
maintain their integrity. Bcl-2 can prevent cytochrome c release and hence caspase
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activation (Cory and Adams, 2002). Survivin, a member of the inhibitor of apoptosis
protein family, has been implicated in protection from apoptosis and regulation of
mitosis. Survivin kinetics differ from that of Bcl-2 in that more than 70 % of the protein
is discharged from the mitochondria into the c)d:osol within 4 hrs of apoptotic stimulation,
suggesting that loss of mitochondrial membrane integrity results in the release not only of
cell death amplifiers but also a cell death antagonist, i.e., survivin (Dohi et al, 2004).
Our study shows that IGF-II mediates RSV effect on cell survival and apoptosis
by regulating the anti-apoptotic proteins Bcl-2 and survivin. Of note proIGF-II had a
more significant effect on Bcl-2 and survivin protein levels than mIGF-II. Similarly
MCF-7 cells transfected with proIGF-II cDNA were protected from RSV-induced
apoptosis, while mIGF-II transfected cells were less protected.
Reports from other laboratories have shown that IGF-I induces promoter activity
of the Bcl-2 gene via a signaling pathway mediated by MAPK kinase 6/p38p
(Pugazhenthi et al, 1999), interestingly we previously showed that RSV only stimulates
IGF-II, not IGF-I, in breast cancer cells and our present study shows that proIGF-II does
not increase Bcl-2 gene expression, but it does increase Bcl-2 protein levels possibly by
affecting its translation rate. This difference between IGF-I and IGF-II effect on Bcl-2
expression is of great significance, due to the fact that both growth factors bind and
activate the same receptor, but their downstream effects are not necessarily the same.
Unique among other inhibitor of apoptosis proteins (lAPs), survivin, like IGF-II,
is selectively expressed during development and in many human cancers, but not in
normal adult tissues, indicating that its overexpression in cancers plays a role in apoptosis
inhibition and tumor progression. RSV has been shown to downregulate survivin in
leukemia cell lines (33), but no pathway has been delineated yet. In the present study, we
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showed that RSV (10"'^) inhibits survivin gene expression through IGF-II downregulation
in MCF-7 hreast cancer cells. Addition of recomhinant human proIGF-II (not mIGF-II)
blocked RSV inhibitory effect on survivin gene expression and protein levels in MCF-7
cells. Similarly, Transfection with mIGF-II or proIGF-II cDNA, protected from RSV-
induced apoptosis, although a more significant effect on cell survival was seen in proIGF-
II transfected cells than in mIGF-II transfected cells. To our knowledge, this is the first
study that shows not only a differential effect induced by the two IGF-II forms on breast
cancer cell survival, hut also identifies IGF-II as a key molecule involved in RSV effects
on the anti-apoptotic proteins Bcl-2 and survivin.
The differential effect of proIGF-II and mIGF-II in regulating anti-apoptotic proteins and
preventing mitochondrial depolarization represents a novel mechanism by which proIGF-
II promotes cancer progression.
Thus, we propose that RSV could increase the risk of breast cancer growth at low
concentration by increasing proIGF-II levels, and that proIGF-II is a key player in the
mechanism of action of RSV and a promising target to develop new therapies for breast
cancer treatment and chemoprevention.
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